Extraction and Biochemical Characterization of Alligator mississippiensis glycosaminoglycans and an Ex-vivo Murine Pilot Study to Test their Potential Effect on a Selected Panel of Genes Associated with Cystic Fibrosis by Estrada Andino, Jose Daniel
Louisiana State University
LSU Digital Commons
LSU Doctoral Dissertations Graduate School
2016
Extraction and Biochemical Characterization of
Alligator mississippiensis glycosaminoglycans and
an Ex-vivo Murine Pilot Study to Test their
Potential Effect on a Selected Panel of Genes
Associated with Cystic Fibrosis
Jose Daniel Estrada Andino
Louisiana State University and Agricultural and Mechanical College
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations
Part of the Life Sciences Commons
This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in
LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please contactgradetd@lsu.edu.
Recommended Citation
Estrada Andino, Jose Daniel, "Extraction and Biochemical Characterization of Alligator mississippiensis glycosaminoglycans and an
Ex-vivo Murine Pilot Study to Test their Potential Effect on a Selected Panel of Genes Associated with Cystic Fibrosis" (2016). LSU
Doctoral Dissertations. 1245.
https://digitalcommons.lsu.edu/gradschool_dissertations/1245
EXTRACTION AND BIOCHEMICAL CHARACTERIZATION OF ALLIGATOR 
MISSISSIPPIENSIS GLYCOSAMINOGLYCANS AND AN EX-VIVO MURINE PILOT 
STUDY TO TEST THEIR POTENTIAL EFFECT ON A SELECTED PANEL OF GENES 









Submitted to the Graduate Faculty of the 
 Louisiana State University and  
Agricultural and Mechanical College  
in partial fulfillment of the 
 requirements for the degree of 












Jose Daniel Estrada Andino 
B.S., Escuela Agrícola Panamericana Zamorano, 2007 





This work is dedicated to my amazing wife Monika and all of my family in Honduras, Germany 













































 I want to express my deepest gratitude to everyone who played a role in the completion of 
this work. First of all I thank God for the daily assurance of purpose in my life and for all the 
people whom he used for my academic, professional, personal and academic growth during the 
past few years. 
 
 To Dr. Jack Losso, thank you so much for being an admirable person, great friend, and an 
inspiring and always supportive mentor. Thank you for trusting in me to conduct such a relevant 
project for the Louisiana alligator industry and for simultaneously allowing me to have a well-
rounded experience through my involvement in national new product development competitions, 
IFT competitions and an amazing food industry internship. Under your mentorship I have become 
a better person and professional.  
 
 To my committee members, Dr. Joan King, Dr. Roger Laine, Dr. Grover Waldrop, Dr. 
Yogesh Saini, Mr. Mark Shirley and Dr. Erin Casey, thank you for your valuable time and 
guidance. Special thanks to Mr. Mark Shirley and Dr. Yogesh Saini for their hands-on support and 
training in the field and laboratory, respectively. 
 
 To all my collaborators in the experiments carried out for this dissertation, Mr. Cristian 
Macoto, Dr. Marvin Moncada, Dr. Luis Espinoza and Ms. Jeimy Menjivar in the processing of 
alligator by-products, Dr. Richard Cooper for allowing me to use his molecular biology laboratory 
iv 
 
and equipment, Dr. George Stanley for his FT-IR training and Dr. Kenneth Smith at Thermo Fisher 
Scientific for his kind support with FT-IR data collection.  
 
 I would also like to thank all my labmates and friends at the School of Nutrition and Food 
Science and around the LSU campus for all their support and encouragement expressed in many 
different ways. Especially, Srikanth, Namrata, Kennet, Ryan, Reynaldo, Alejandro and Damir. To 
my Baton Rouge parents Mark and Alicia, your friendship and care have made this town feel like 
home. To my SBRPC family, thank you for supporting me in prayer and also in many practical 
ways even before I arrived here.  
 
 Finally, to my wife Monika and my family in Honduras, Poland and Germany. Thank you 
for supporting my goals and always believing in my potential. I would not have made it so far 
without all of you. Monika, your willingness to move from Germany to Baton Rouge gave me the 

















TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ........................................................................................................... iii 
LIST OF TABLES ........................................................................................................................ vii 
LIST OF FIGURES ..................................................................................................................... viii 
ABBREVIATIONS INDEX ........................................................................................................... x 
ABSTRACT ................................................................................................................................. xiv 
CHAPTER 1 INTRODUCTION .................................................................................................... 1 
CHAPTER 2 LITERATURE REVIEW ......................................................................................... 5 
2.1. Louisiana Alligator Farming ........................................................................................ 5 
2.2. Medicinal Properties of Crocodilians ........................................................................... 6 
2.3. Hyaluronic Acid and Sulfated Glycosaminoglycans .................................................... 9 
2.3.1. Classification and Structures ................................................................................. 9 
2.3.2. Biosynthesis .......................................................................................................... 9 
2.3.3. Signaling and Biological Functions of Hyaluronan ............................................ 12 
2.3.4. Degradation ......................................................................................................... 17 
2.3.5. Sources ................................................................................................................ 18 
2.4. Cystic Fibrosis ............................................................................................................ 21 
2.4.1. Introduction ......................................................................................................... 21 
2.4.2. History of Cystic Fibrosis ................................................................................... 22 
2.4.3. The Cystic Fibrosis Transmembrane Conductance Regulator Protein ............... 23 
2.4.4. Diagnosis ............................................................................................................. 26 
2.4.5. Airway Pathophysiology in Cystic Fibrosis ........................................................ 26 
2.4.6. Current Treatment ............................................................................................... 30 
2.4.7. Markers of Inflammation in Cystic Fibrosis ....................................................... 35 
CHAPTER 3 MATERIALS AND METHODS ........................................................................... 37 
3.1. Experimental Design and Statistical Analysis ............................................................ 37 
3.2. Materials ..................................................................................................................... 37 
vi 
 
3.3. Extraction of GAGs from Alligator Carcasses, Feet and Backstraps ......................... 39 
3.4. Extraction of GAGs from Alligator Eyeballs ............................................................. 42 
3.5. Determination of Sulfated GAGs, HA and Total GAGs Content .............................. 43 
3.6. GAGs Size Analysis ................................................................................................... 44 
3.7. Digestion of GAGs by Type-1 Hyaluronidase and Chondroitinase ABC .................. 45 
3.8. Determination of Protein and Mineral Content .......................................................... 46 
3.9. Structure Characterization by FT-IR Spectroscopy .................................................... 47 
3.10. Cystic Fibrosis Ex-Vivo Scnn1b-Tg Mice Pilot Study ............................................ 47 
3.10.1 Transgenic Mice Generation and PCR Genotyping ............................................ 47 
3.10.2 Animal Husbandry .............................................................................................. 48 
3.10.3 Trachea Harvesting ............................................................................................. 48 
3.10.4 MTEC Isolation ................................................................................................... 49 
3.10.5 MTEC Submerged Culture ................................................................................. 50 
3.10.6 MTEC Differentiation in Air-Liquid Interface Culture ...................................... 50 
3.10.7 MTEC Treatment with AEB GAGs .................................................................... 51 
3.10.8 Cell Lysis and RNA Purification ........................................................................ 52 
3.10.9 cDNA Generation and PCR Microarray ............................................................. 53 
3.10.10 Transglutaminase Activity Assay .................................................................... 56 
CHAPTER 4 RESULTS AND DISCUSSION ............................................................................. 58 
4.1. Yields of Sulfated GAG, HA and Total GAG from Alligator By-products ............... 58 
4.2. Agarose Gel Electrophoresis of Alligator GAGs ....................................................... 64 
4.3. Enzymatic Assays ....................................................................................................... 66 
4.4. Protein and Mineral Contents of Alligator By-product GAGs ................................... 69 
4.5. FTIR Spectra of Alligator By-product GAGs ............................................................ 74 
4.6. Scnn1b-Tg MTEC Gene Expression Analysis ........................................................... 79 
CHAPTER 5 CONCLUSIONS AND FUTURE STUDIES ......................................................... 98 
REFERENCES ........................................................................................................................... 101 





LIST OF TABLES 
 
Table 3.1. MTEC Basic Media (10% FBS) Formulation ............................................................. 49 
Table 3.2. MTEC+Y27632 Media Formulation ........................................................................... 51 
Table 3.3. MTEC+NuSerum Media Formulation ......................................................................... 52 
Table 3.4. Murine CF RT2 Profiler PCR Array Gene List ........................................................... 54 
Table 4.1. lligator By-product Processing Results........................................................................ 58 
Table 4.2. Composition of Alligator GAGs .................................................................................. 61 
Table 4.3. Assignment of FTIR Bands for Standards and Alligator GAGs ................................. 76 
Table 4.4. NA Extraction and PCR Control Results ..................................................................... 80 



















LIST OF FIGURES 
 
Figure 2.1. Repeating disaccharide units of the GAGs ................................................................. 10 
Figure 2.2. Addition of GlcNAc and GlcA by the HA transmembrane synthases ....................... 11 
Figure 2.3 Binding of HA to alveolar septal elastic fibers upon intratracheal administration may 
prevent their degradation by elastases .......................................................................................... 15 
Figure 2.4. Model showing the proposed domain structure of the CFTR .................................... 23 
Figure 2.5. Classification of CFTR mutations .............................................................................. 24 
Figure 2.6. Low volume hypothesis for CF .................................................................................. 25 
Figure 2.7. Prevalence of Respiratory Microorganisms by Age Cohort, 2014 ............................. 30 
Figure 2.8. Chronic Medication Use in CF Patients, 1995-2014 .................................................. 31 
Figure 3.1. Process diagram of GAG extraction from alligator ACS, AFT and ABS. ................. 41 
Figure 3.2 Process diagram of GAG extraction from AEB. ......................................................... 42 
Figure 4.1. Standard curve for sulfated GAG assay. .................................................................... 59 
Figure 4.2. HA competitive ELISA standard curve ...................................................................... 61 
Figure 4.3. Calibration curve for HA standard carbazole reaction ............................................... 63 
Figure 4.4. Electrophoresis of ACS, AFT, ABS and AEB GAGs on a 0.75% agarose gel. ......... 65 
Figure 4.5. Electrophoresis of ACS, AFT, ABS and AEB GAGs on a 0.75% agarose gel after 
dialysis (50 kDa MWCO). ............................................................................................................ 67 
Figure 4.6. Electrophoresis of ACS, AFT, ABS and AEB GAGs on a 0.75% agarose gel after 
HAase digestion. ........................................................................................................................... 68 
Figure 4.7. Electrophoresis of ACS GAGs on a 0.75% agarose gel after ChrAse digestion. ...... 70 
Figure 4.8. Protein content in alligator by-product GAG extracts ................................................ 71 
Figure 4.9. Mineral content in alligator by-product GAG extracts............................................... 74 
Figure 4.10. FTIR-ATR spectra of alligator GAGs ...................................................................... 75 
ix 
 
Figure 4.11. FTIR spectra of AFT GAGs (top) and streptococcal HA-salt (bottom). .................. 78 
Figure 4.12. Electrophoresis of AEB GAGs used for MTEC treatment after dialysis (50 kDa 
MWCO) and autoclaving (121.1°C for 5 min) ............................................................................. 79 
Figure 4.13. Capillary electrophoresis electropherograms and gels of RNA extracted from 
control and AEB-GAG treated Scnn1b-Tg MTEC ....................................................................... 81 
Figure 4.14. Non-supervised hierarchical clustering heat map of the differentially expressed 
genes in treated and untreated (control) Scnn1b-Tg MTEC in ALI culture ................................. 82 
Figure 4.15. Distribution of gene regulation due to AEB GAGs treatment of Scnn1b-Tg MTEC 
in ALI culture ................................................................................................................................ 83 
Figure 4.16. Non-supervised hierarchical clustering heat map with dendrograms indicating co-
regulated genes of the significantly (p≤0.05) regulated (>1.5 fold) genes in treated and untreated 























ABS   alligator backstraps 
ACS   alligator carcasses 
AEB   alligator eyeballs 
AFT   alligator feet 
ALI   air-liquid-interface 
AMP   adenosine mono-phosphate 
AMPK   AMP-activated kinase 
ANOVA  analysis of variance 
ASL   airway surface liquid 
ATP   adenosine triphosphate 
BAL   bronchoalveolar lavage 
BCA   bicinchoninic acid 
BSA   bovine serum albumin 
cAMP-PKA  cyclic adenosine monophosphate-dependent protein kinase A 
CCL27  cutaneous T cell-attracting chemokine 
CF   cystic fibrosis 
CFTR   cystic fibrosis transmembrane conductance regulator 
ChrAses  chondroitinases 
COPD  chronic obstructive pulmonary disease 
CPC  cetylpyridinium chloride 
CRBD  completely randomized block design 
CS  chondroitin sulfate 
CT  threshold cycle 
DMB  dimethylmethylene blue 
DMEM  Dulbecco’s Modified Eagle Medium  
xi 
 
DNase  deoxyribonuclease 
DS  dermatan sulfate 
ECM  extracellular matrix 
EDTA  ethylenediaminetetraacetic acid 
ENaC  epithelial sodium channel 
FBS  fetal bovine serum 
FEV1  forced expiratory volume in 1 second 
FT-IR  fourier transform infrared spectroscopy 
FVC  forced vital capacity 
GAGs  glycosaminoglycans 
GalNAc  n-acetylgalactosamine 
GDC  genomic DNA control 
GlcA  glucuronic acid 
GlcNAc  n-acetylglucosamine 
HA  hyaluronic acid 
HAases  hyaluronidases 
HARE  hyaluronan receptor for endocytosis 
HAS1-3  hyaluronic acid synthases 1-3 
HCl  hydrochloric acid 
HIV-1  human immunodeficiency virus type 1 
HP  heparin 
HS  heparan sulfate 
HSP  heat shock protein 
HSV-1  herpes simplex virus type 1 
HMW  high molecular weight 
HTS  hypertonic saline 
ICP-AES  inductively coupled plasma atomic emission spectrometry 
xii 
 
IdA  iduronic acid 
IL-1β  interleukin 1 beta 
IL-6  interleukin 6 
IL-8  interleukin 8 
IL-10  interleukin 10 
IRAK  interleukin 1 associated kinase-M 
KS  keratan sulfate 
LMW  low molecular weight 
LYVE1  lymphatic vessel endothelial hyaluronan receptor 1 
MCC  mucociliary clearance 
MIP-2  macrophage inflammatory protein 2 
MMP  matrix metalloproteinase 
MMW  medium molecular weight 
MSD1-2  membrane spanning domains 1 and 2 
MTEC  mouse tracheal epithelial cells 
MTEC+Y27632 MTEC media containing Y27632 ROCK inhibitor (10 µM) 
MTEC+NuSerum MTEC media containing NuSerum (2%)  
MWCO  molecular weight cut-off 
NBD1-2  nucleotide binding domains 
NE  neutrophil elastase 
NF- κβ  nuclear factor kappa beta 
oHA  hyaluronic acid oligosaccharides 
PBS  phosphate buffered saline 
PBST  phosphate buffered saline-Tween 
PCR  polymerase chain reaction 
PPARƴ  peroxisome proliferator-activated receptor-gamma 
PPC  positive PCR control 
xiii 
 
R2  correlation coefficient  
RD  regulatory domain 
RHAMM  receptor for hyaluronan mediated motility 
ROS  reactive oxygen species 
RTC  reverse-transcription control 
SD  standard deviation 
STAT3  signal transducer and activator of transcription 3 
TBE  tris borate-EDTA 
TCA  trichloroacetic acid 
TGAse  tissue transglutaminase 
TLRs  toll-like receptors 
TNF-α  tumor necrosis factor 



















Cystic fibrosis (CF) is a genetic disorder with a median survival age of 40.7 years. Chronic 
airway inflammation and dehydration are critical features of CF. The size and structure-dependent 
hydration and anti-inflammatory properties of glycosaminoglycans (GAGs) such as hyaluronic 
acid (HA) may help ameliorate these symptoms. The GAGs contained in farmed Alligator 
mississippiensis by-products offer a potential to improve waste management practices and increase 
revenue in the alligator industry, through their development for use in biomedical applications. 
This study aimed to efficiently extract and characterize GAGs from alligator carcasses (ACS), 
backstraps (ABS), feet (AFT) and eyeballs (AEB), to evaluate their effects on CF-like airways ex-
vivo. Samples were collected from local alligator processing facilities and extractions were 
conducted according to a randomized complete block design. The contents of sulfated and non-
sulfated GAGs were determined using dimethylmethylene blue and HA ELISA assays, 
respectively. Total GAG content was confirmed by the carbazole reaction assay. Protein content, 
mineral content and molecular weight (MW) were determined by the bicinchoninic acid assay, 
inductively coupled plasma and 0.75% agarose electrophoresis, respectively. FTIR spectroscopy 
was conducted to fingerprint the structures of the extracted GAGs. Multi-step processes for the 
extraction of GAGs from alligator by-products were developed and ABS had the highest (p≤0.05) 
total GAG content (15.53±0.27 mg/g), followed by AFT (4.72±0.05 mg/g), AEB (0.79±0.01 mg/g) 
and ACS (0.60±0.00 mg/g). These results are equivalent to ~2.13 g GAGs per harvest-size farmed 
alligator or an estimated GAG production of ~0.73 tons/year in Louisiana. The GAGs in all 
samples were predominantly (>97%) HA with a poly-disperse MW of up to 1600 kDa. FTIR 
revealed spectra showing characteristic GAG features such as -OH, -NH, -CH and amide signals 
xv 
 
from residual protein, comparable to previous studies on animal-sourced GAGs. Ex-vivo gene 
expression analysis of Scnn1b-Tg mice tracheal epithelial cells indicated that AEB GAGs (0.5 
mg/12 mm insert) have the potential to regulate the expression of genes which may aid in restoring 
the protease/anti-protease balance, reducing inflammation, and regulating ASL osmotic 
homeostasis. Alligator GAGs may also aid in the treatment of other inflammatory conditions such 



































The state of Louisiana has the largest alligator (Alligator mississippiensis) industry in the 
United States. A total of over 350,000 farm-raised and wild alligators are harvested yearly through 
a world-renowned sustainable system managed by the Louisiana Department of Wildlife and 
Fisheries. This model generates a significant revenue, as well as protection of the wetland habitats 
[1]. In the processing of slaughtered alligators for their skin and meat, the industry generates waste 
which is currently being disposed in landfills or marketed at very low prices. These by-products 
contain valuable anti-inflammatory glycosaminoglycans (GAGs) that can be extracted in a 
promising effort to improve current waste management practices and further increase the 
industry’s value. 
 
Hyaluronic acid (HA) is a linear, negatively charged, highly hydrophilic and non-sulfated 
GAG found mainly in the extracellular matrix (ECM) in the form of sodium salt [2,3]. This high 
molecular weight (HMW) GAG, which is degraded by hyaluronidases (HAases), chondroitinases 
(ChrAses) and reactive oxygen species (ROS), possesses multiple size-dependent signaling 
properties. There is consensus that larger HA chains have anti-inflammatory properties and smaller 
ones have pro-inflammatory activity, however there is no clear categorization about the molecular 
weight of HA [4–6]. HA fragments (6-12 disaccharides) have been reported to significantly 
increase the expression of inflammatory cytokines and tissue degrading enzymes such as matrix 
metalloproteinases (MMP) [7]. In the airways, HA interacts with a variety of cell surface receptors 
and HA-binding proteins to activate intracellular events through various pathways [8,9]. 
Inflammation in mice cystic fibrosis (CF) airways has been effectively mitigated by nebulized HA 
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as measured by the reduction of TNF-α, myeloperoxidase activity, ROS and tissue 
transglutaminase (TGAse) activity [10]. Moreover, Scuri and Abraham reported dose dependent 
inhibition of human NE induced airway responses in sheep pretreated with 150 or 300 kDa HA 
[11]. It has also been proposed that the water binding properties of HA may increase the elasticity 
of lung elastic fibers, thus improving pulmonary mechanics [12] or purulent mucus clearance. The 
abundance of carboxyl groups in HA may also result in an interaction with Ca2+ [13,14], therefore 
limiting TGAse inflammatory activity in the airways of CF patients.  
 
CF is a severely life shortening genetic disorder that globally affects around 70,000 
individuals primarily of Caucasian descent. Mutations in both copies of the CF transmembrane 
conductance regulator (CFTR) gene disrupt normal production of the CFTR protein which is a 
chloride channel expressed in the epithelium of multiple organs including the lungs [15]. The 
defective CFTR results in abnormal transport of chloride and sodium across the cell membrane 
which leads to a high morbidity due to obstructive lung disease [10,15,16]. CF is also characterized 
by an early and dysregulated inflammatory scenario in the airways which has been associated with 
increased levels of pro-inflammatory cytokines and enzymes [17–21]. The extent of inflammatory 
response in these patients is disproportionately increased compared to patients without CF both in 
presence or absence of bacterial infection [22]. Upregulation of nuclear factor kappa beta (NF-κβ) 
increases the production of interleukin-8 (IL-8) and tumor necrosis factor alpha (TNF-α), which 
mediate neutrophil activity and the secretion of neutrophil elastase (NE), a serine protease 
designed for bacterial phagocytosis but that can also degrade airway tissues and cause lung damage 
[18,23,24]. Currently, anti-inflammatory treatments with corticosteroids and high-dose ibuprofen 
have shown benefits, however side-effects limit their continuous use [25,26]. Furthermore, TGAse 
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is an enzyme that catalyzes cross-links or deamidation of target proteins in the presence or absence 
of Ca2+ [27,28] and it has been shown that innate increased oxidative stress in CF airway epithelia 
induces TGAse up-regulation. For this reason TGAse has been recognized as a potential target 
enzyme for healing of lung inflammation and injuries [29,30].  
 
HA is a natural component of the respiratory system that has been safely used in European 
CF Centers to improve the tolerability of hypertonic saline and to test its efficacy in the treatment 
of bacterial rhinosinusitis in combination with tobramycin [24,31,32]. Globally, the HA market is 
estimated over US$1 billion in the biomedical (knee osteoarthritis, ophthalmic procedures and 
dermal fillers), cosmetic and food industries [33,34]. This compound alone or in the presence of 
other GAGs may aid in the down-regulation of the chronic and uncontrolled pro-inflammatory 
responses in CF by reducing the expression of potent cytokines and TGAse. In aggregate the 
currently available information on CF, GAGs, and the abundance of waste products containing 
GAGs in the Louisiana alligator industry, support the relevance of extracting A. mississippiensis 
by-product GAGs to evaluate their potential to ameliorate inflammation, mediate osmotic 
homeostasis, and recover the protease/anti-protease balance in CF airways, as well as potentially 
generate economic development through increased revenue and creation of new labor and high 
technology jobs.  
 
The main objective of this research was to determine the yield and biochemical 
characteristics of A. mississippiensis by-product GAGs and explore their potential regulatory role 
on a selected panel of genes associated with CF in mice CF-like airways ex-vivo. The specific aims 
that derive from this objective are:  
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1. To develop a method for the extraction of GAGs from alligator carcasses (ACS), feet 
(AFT) and backstraps (ABS). 
 
2. To develop a method for the extraction of GAGs from alligator eyeballs (AEB). 
 
3. To quantify and characterize the GAGs extracted from ACS, AFT, ABS and AEB. 
 
4. To evaluate the effects of A. mississippiensis AEB GAGs on the ex-vivo expression of 




























2.1. Louisiana Alligator Farming 
American alligators (Alligator mississippiensis) have been used commercially for their 
valuable leather since the 1800s and their harvest was generally unregulated through the 1900s. 
This resulted in severely reduced harvests in the 1950s and a hunting ban from 1962 to 1972 [35]. 
Since 1972, Louisiana alligators have been managed as a commercial, renewable natural resource 
by the Louisiana Department of Wildlife and Fisheries through a successful and world renowned 
sustained use program. The program regulates harvest, assures long term benefits to the survival 
of the species and provides significant economic benefits and incentives to private landowners to 
protect alligator wetland habitats [36]. After rebuilding the population through research, 
management and law enforcement in the 1960’s, the wild harvest from 1972 through 2014 
produced over 975,000 wild skins. Currently, most of the A. mississippiensis farming activity 
occurs in the southeastern United States and it is led by Louisiana [37] which supplies ca. 20% of 
the global commercial crocodilian skins [38]. In January 2014, there were 34 licensed farms with 
stock mainly in the Livingston, Terrebonne, Lafourche, St. Tammany and Vermilion parishes [36]. 
In calendar year 2014 alone, Louisiana sold 341,887 farm raised skins and 35,945 from wild 
harvest. Including all skins, meat and egg collection the industry generated over $100,000,000 in 
economic benefit to the state of Louisiana [39]. Singapore, Japan, Germany, France and Italy are 
the main high-end markets for skins at an average $8.50/cm (width) in 2013, while the meat (~3 




Since 1986, alligator eggs have been collected from the wild between the months of June 
and August to be incubated in private hatcheries. Eggs are incubated at ~30 to 34°C from 1.5 to 3 
months [40]. Most of the hatchlings are raised for their hide and meat, however to maintain the 
wild population stable, ~14% of the hatchlings are returned to the same location where they were 
collected [41]. The remaining ~86% of the hatchlings are placed in different types of indoor 
buildings (large round sheds, small rectangular sheds, etc.) under controlled air and water 
temperature (80°F), animal density (1 ft2/ alligator of less than 24 inches long and 3 ft2/ alligator 
of 25-48 inches long) and feeding conditions (diet with 45-55% protein) during 10 to 18 months. 
After slaughtering alligators at market length (≥ 4 ft.) using approved methods, hide and meat 
processors generate approximately 500 tons of by-products per year including ACS, AFT, ABS 
and AEB that are currently disposed in landfill or sold at very low prices (1¢ per lb) for pet foods. 
However, with increased regulations regarding pet feed, few animal feed processors are buying 
these by-products. Efforts have been made to better understand and increase the profitability of 
alligator carcasses and by-products [42], however little has been reported to date regarding feasible 
opportunities. Teeth, heads and skulls are also used as tourist curios. To the best of our knowledge, 
there are currently no processes or businesses established to utilize alligator by-products in a 
profitable and sustainable manner. 
 
2.2. Medicinal Properties of Crocodilians 
Since ancient times, zootherapy has been an alternative in the treatment of different 
illnesses. “Medicine men” in different tribes around the world have used animal-based traditional 
medicine for centuries. The folk medicinal use of crocodilians has been documented in populations 
in Mexico, India, and Nigeria [43–45] which leads to investigation of the existence of therapeutic 
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and bioactive compounds in these organisms. This becomes significant considering that these 
reptiles have a low incidence of diseases in the highly contaminated conditions of marshes and 
swamps and most of their wounds heal properly and completely [46]. Recently, studies conducted 
in South Africa and the United States investigated the antimicrobial, amoebicidal, anti-
inflammatory and antiviral properties of crocodilian body parts [47–49]. These properties may 
partially explain the evolutionary success of crocodilians while living in wild and farm aquatic 
environments teeming with bacteria and/or agricultural residues [46,50,51]. 
 
Crocodile-based treatments play a role in the indigenous medicine of Nigerian 
communities. Nile crocodile (Crocodylus niloticus) has been reported to be used in the treatment 
of rheumatism (whole tail bones), snake poisoning (scales or tip of tail) and male impotency (whole 
male animal) [44], although scientific proof is lacking and the placebo effect not tested. In a review 
of traditional medicine in the state of Kerala, India, Padmanabhan and Sujana [43] reported the 
use of Crocodile palustris eggs by tribal medicine men for asthma treatment. Even though the 
GAG composition of crocodilian eggs has not been reported in detail, the presence of GAGs is 
known [52]. Abundance of GAGs, including HA, has been reported in all components of the 
chicken egg [53]. In China, crocodile bile is another folk medicine alternative remedy for asthma 
and allergies [54]. The Chinese also believe that crocodile meat can help asthma sufferers, a person 
getting a cold, and even improve the strength of the lungs [55], although such claims lack scientific 
basis. Farmed crocodile tail oil has been evaluated for the treatment of microbial infections and 
inflammatory conditions [47]. Buthelezi and others, showed that Staphylococcus aureus, 
Klebsiella pneumoniae and Candida albicans are susceptible to 6-15% (w/v) oil preparations. 
Furthermore, in an induced auricular edema mice model they showed that oral administration and 
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topical application of crocodile oil resulted in optimal anti-inflammatory effects after 3 h and 12 h, 
respectively. Many functional properties have been attributed to collagen and gelatin from 
different animal sources [56] and it could be that other non-proteinaceous components of the ECM, 
such as HA extracted along with the collagen may account for the claimed bioactivities. 
 
It has been observed that American alligators (A. mississippiensis) often sustain serious 
injuries and damage due to territorial disputes with other alligators. However, these reptiles exhibit 
a remarkable ability to heal rapidly and without infection. In a cell based assay, serum collected 
from wild alligators demonstrated antiviral activity against human immunodeficiency virus type 1 
(HIV-1), West Nile virus and Herpes simplex virus type 1 (HSV-1). These and other reports by 
Merchant and others suggest that alligators have evolved a complex innate immune system, 
however other mechanisms such as the serum complement system are also active [48,49,57]. 
Antimicrobial peptides extracted from A. mississippiensis leukocytes have displayed antibacterial 
activity against Gram negative and positive bacteria, antifungal activity against six pathogenic 
Candida yeast spp. species and antiviral properties against HIV-1 and HSV-1 [58]. Four novel 
antimicrobial peptides (leucrocins I-IV) were recently extracted and purified from Siamese 
crocodile (Crocodylus siamensis) white blood cells [59]. Multivariate analyses of the serum from 
all twenty-three known living members of the Crocodylia were tested for antibacterial activity 
against eight bacterial species and it was revealed that the innate immune activities of the 
Alligatoroidea were remarkable and statistically higher than those of the Crocodyloidea and 
Gavialoidea [60]. This brief review demonstrates that there is evidence in favor of some potential 
alligator-based medicine treatments, however more information must be generated to support these 
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practices, determine the bioactive compounds responsible for the claimed effects and elucidate 
action mechanisms.  
2.3. Hyaluronic Acid and Sulfated Glycosaminoglycans 
2.3.1. Classification and Structures  
GAGs are large heteropolysaccharides that are composed of repeating disaccharide units. 
All GAGs are made of an amino sugar, typically n-acetylglucosamine (GlcNAc) or n-
acetylgalactosamine (GalNAc), and a uronic acid, typically glucuronic acid (GlcA). However, 
there are two main types of GAGs. Sulfated GAGs include heparan sulfate (HS), of which heparin 
(HP) is a highly sulfated member, which are based on D-GlcNAc and D-GlcA or iduronic acid 
(IdA), respectively. Chondroitin sulfate (CS) is based on D-GalNAc and D-GlcA, while dermatan 
sulfate (DS) is composed of D-GalNAc and L-IdA. Keratan sulfate (KS) is the most heterogeneous 
GAG and is based on D-GalNAc and D-galactose. The non-sulfated GAGs include hyaluronan, 
also called sodium hyaluronate or HA, and it is composed of D-GlcNAc and D-GlcA bound 
together through β1,4 and β1,3 glycosidic bonds, respectively (Figure 2.1) [61–64]. Since HA is 
the major non-proteinaceous component of the ECM [5] and consequently the most abundant GAG 
found in alligator by-products, this literature review will focus mainly on HA’s features including 
biosynthesis, degradation, biological properties, sources and applications. 
 
2.3.2. Biosynthesis  
HA is ubiquitously expressed in the ECM of the animal kingdom. It was first identified in 
the vitreous humor of cattle eyes by Meyer and Palmer in 1934 [65]. In contrast to sulfated GAGs 
that are produced in the Golgi apparatus, HA is synthesized at the inner face of the plasma 




Figure 2.1. Repeating disaccharide units of the GAGs [Adapted from 10]. *HS 
shows a lower degree of sulfation (0.6-1.5 sulfates/disaccharide) than HP (2.3-









transferases or HA synthases (HAS1, HAS2, and HAS3) (Figure 2.2) [67]. Although these 
isozymes synthesize an identical HA molecule, they have been shown to have distinct stability, 
elongation rate of HA and Km values, which potentially regulate the biological function of HA [68]. 
HAS2 is the main HA synthetic enzyme in adult cells and it generates HA with an extremely large   
and broad molecular weight distribution (>2000 kDa or a degree of polymerization around 5,000 
disaccharides), whereas HAS1 (200-2000 kDa) and HAS3 (100-1000 kDa) produce shorter 
dipeptide chains [61,68]. HASs are regulated by a number of mechanisms from temporal 
expression patterns during development [69], to a wide range of cytokines and receptors [70] 
and/or availability of substrates for HA synthesis [61].  
 
 
Figure 2.2. Addition of GlcNAc and GlcA by the HA transmembrane synthases 
 
Over decades, there has been no consensus or clear nomenclature in regards to the 




= UDP-GlcNAc = UDP-GlcA 
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designations: HMW-HA for >1000 kDa, low molecular weight HA (LMW-HA) for <1,000 kDa 
to >20 monosaccharides, and HA oligosaccharides (oHA) for <20 monosaccharides in length [6]. 
Monslow and others (2015) categorized HA sizes more distinctly as HMW-HA (>1000 kDa), 
medium molecular weight HA (MMW-HA) (250-1000 kDa), LMW-HA (10-250 kDa) and oHA 
(<10 kDa) [5]. Monslow’s classification will be followed in this study. HA is usually found in 
synovial fluid, vitreous humor and connective tissue. Sulfated GAGs are smaller than HA and their 
size ranges from 4-70 kDa. CS has a molecular weight of 5-50 kDa and is found in cartilage, 
tendon, ligaments and arteries. DS (15-40 kDa) is found in skin, blood vessels and heart valves 
and KS (4-19 kDa) is found in the cornea and in cartilage aggregated with CS. HP (10-12 kDa) is 
a naturally occurring anticoagulant stored in mast cell vesicles especially in the liver, lungs and 
skin. HS (10-70 kDa) is ubiquitously expressed in animal cell surfaces [63,64,66]. 
 
2.3.3. Signaling and Biological Functions of Hyaluronan  
Despite their simple chemical composition, GAGs fulfill several distinct molecular 
functions. For many years HA was considered an inert filler in the ECM, however it is now known 
that it possesses a plethora of often opposing size-dependent biological functions [71]. HA 
contributes not only to the structural and physiological characteristics of tissues, but also mediates 
cell behavior during morphogenesis, tissue remodeling, inflammation and diseases. As a signaling 
molecule, HA interacts with a variety of cell surface receptors to activate intracellular events to 
mediate cell functions [8]. HA is the main ligand to CD44, a receptor expressed on the surface of 
almost all human cells involved in many cell-cell interactions and in a wide variety of cellular 
functions [61,72]. A study by Teder and others suggests that CD44 plays a critical role in HA 
clearance and homeostasis following lung injury which influences the recovery from pulmonary 
inflammation. Moreover, they showed that mice accumulate LMW-HA following bleomycin 
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induced lung injury, however after inflammation is resolved, HMW-HA synthesis is predominant 
[73]. LMW-HA levels in the bronchoalveolar lavage (BAL) of CD44-negative mice have been 
reported to be 2-fold higher than wild type [74]. Jiang and others showed that HA fragments induce 
pro-inflammatory macrophage inflammatory protein-2 (MIP-2), the murine equivalent to human 
IL-8, and lung epithelial cell-specific overexpression of HMW-HA was protective against lung 
injury [75]. Similarly, mice and macrophages exposed to HMW-HA prior to LPS injection had 
greatly decreased interleukin-6 (IL-6) and TNF-α levels in serum and mRNA expression, 
respectively. This effect was not observed in CD44-negative mice or macrophages [76]. HA can 
also modulate key cancer cell functions through interaction with its CD44 and receptor for 
hyaluronan mediated motility (RHAMM) receptors [77]. 
 
The interaction of HA with the RHAMM can also trigger several signaling cascades 
including the NF-κβ pathway [61]. RHAMM is normally localized intracellularly and is only 
released by some poorly defined stimuli. Extracellularly, RHAMM associates with CD44 and upon 
binding with HA, it activates intracellular signaling pathways [8]. The interaction of RHAMM 
with a oHA (6-mer) was shown to play an important role in the inflammatory and fibrotic processes 
resulting from acute lung injury by bleomycin in mice [78]. A study using primary tracheal 
epithelial cell cultures treated with HA (200 kDa) at 50 ug/mL proposed a model in which HA 
serves a key role in mucosal host defense. HA, through its interaction with RHAMM, stimulated 
ciliary beating and hence the clearance of foreign material from mucosal surfaces while still 




Toll like receptors (TLRs) are able to rapidly initiate the innate immune response, which 
represents the first defense against pathogens. The negative and positive effects of TLRs 
interaction with LMW-HA and HMW-HA, respectively, have been previously reviewed [61]. In a 
murine lung injury model, the knockout of TLR2 and TLR4 abolished completely the activation 
of chemokines in macrophages. Moreover, oHA induced the nuclear translocation of NF-κβ and 
production of TNF-α [75]. The expression of MMP-2 and IL-8 is also stimulated by HA fragments 
in part by signaling of TLR4 [80]. On the other hand in human monocytes, HMW-HA via its 
engagement with CD44 and TLR4 is a positive regulator of IL-1R-associated kinase-M (IRAK), 
which is thought to be a negative regulator of inflammatory TLR signaling [81]. HA of different 
sizes can also signal through the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE 1) 
and the hyaluronan receptor for endocytosis (HARE). HARE has a complex structure including 
several HA and other GAG binding motifs. The binding of human or rat HARE with HA of an 
optimum size of 140 kDa has been shown to stimulate the activation of NF-κβ [82]. In aggregate, 
affinity for receptors, receptor clustering and uptake will differ depending on HA size, which may 
affect downstream signaling cascades. Cell type may also be a driver of differences in HA 
signaling. 
 
Binding of HA with tumor necrosis factor-alpha stimulated gene-6 (TSG-6) is involved in 
the mediation of lymphocyte migration during inflammation. This binding results in the formation 
of fibrils that are pro-adhesive to lymphocytes which prevents direct contact of inflammation 
promoting receptors and elastases with the underlying tissues [83–86] (Figure 2.3). HA cables 
synthesized by mouse or human airway smooth muscle cells can also form independently without 
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the presence of TSG-6. These cables are capable of binding a large number of leukocytes and can 
sequester pro-inflammatory chemokines through interactions with CS and DS chains [87,88].  
 
An investigation on airway responses in sheep showed that the preventive inhibitory effects 
of inhaled HA (3, 6, 7 or 15 mg in 3 ml phosphate buffered saline (PBS)/ sheep) against human 
NE-induced bronchoconstriction, could extend for at least 8 hours. Both LMW-HA and MMW-
HA showed a dose-dependent inhibition of the inflammatory responses, however above 150 kDa, 
dose and not molecular weight was the key for effective protection [11]. It has been proposed that 
 
 
Figure 2.3 Binding of HA to alveolar septal elastic fibers upon intratracheal 
administration may prevent their degradation by elastases [86] 
 
this protective effect of HA may be accompanied by an improvement in pulmonary mechanics due 
to HA’s special ability to retain water which may help increase the elasticity of lung elastic fibers 
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[12]. Furthermore, lipopolysaccharide-induced TNF-α, IL-6, and interleukin-1 beta (IL-1β) in 
human macrophages have been dose-dependently suppressed by different doses of 2,700 kDa HA 
(0.01, 0.1 and 1 mg/ml). HA (800 kDa) showed no significant effect even at 3 mg/ml. The same 
study proposed injection of HA into arthritis joints as an anti NF-κβ agent [89]. 
 
Due to its biocompatibility, biodegradability, non-immunogenicity, water binding 
properties and receptors (CD44, RHAMM, TSG-6, HARE, LYVE 1), HA has drawn attention in 
the field of biopharmaceutics. HA-drug conjugates may be used to increase the solubility, 
permeability and bioavailability of several anti-cancer and anti-inflammatory drugs [90].  
 
Iovu and others have thoroughly reviewed the anti-inflammatory activity of CS in 
osteoarthritis. CS and/or its disaccharides reduce inflammation (TNF-α, IL-1β, ROS and nitric 
oxide) in joint chondrocytes and synovial membrane through the inhibition of NF-κβ nuclear 
translocation [91]. The role of CS in synovial angiogenesis modulation has been suggested by 
Lambert and others in a study using biopsies from normal and inflammatory osteoarthritic 
membranes. Synovial biopsies from inflamed areas expressed pro-angiogenic phenotypes 
promoted by IL-1β and CS (10, 50, 200 µg/ml) dose-dependently reversed this effect [92]. In a 
psoriasis model using normal human keratinocytes, CS (200 or 1000 µg/ml) effectively 
downregulated the NF-κβ and signal transducer and activator of transcription 3 (STAT3) pathways 
[93]. These effects limited the release of key psoriatic pro-inflammatory cytokines such as TNF-
α, IL-8, IL-6 and the cutaneous T cell-attracting chemokine (CCL27). HA, CS and DS extracted 
from fish have been shown to reduce gliadin-mediated inflammation, in a celiac disease model 
using human Caco-2 cells, through a decrease in the production of IL-1β [94]. The biological 
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functions of CS and DS have also been reviewed in the light of their structural interactions with 
microbes, cell adhesion molecules and growth factors [95]. Octasaccharides of over-sulfated CS 
can inhibit herpes simplex virus infections and a specific CS sequence has also been shown to be 
a potential target for the treatment of malaria [96,97]. Highly sulfated CS and DS bind strongly 
with key liver regeneration growth factors and therefore may be potential candidates for 
development of therapeutics [95]. Tissue regeneration properties in the central nervous system 
have also been attributed to CS disaccharides [98]. Regarding tumor growth, it has been shown in 
vivo that cisplatin-CS liposomes are avidly internalized by highly metastatic liver cancer cells 
which results in cell death [99]. It has also been reported that sulfated GAG-rich wound fluids 
markedly inhibit the antibacterial action of the antibacterial peptide LL-37 through specific GAG-
LL-37 hydrophobic interactions and hydrogen bonding [100]. Finally, HA and the sulfated GAGs 
might also be therapeutic agents in other diseases with strong inflammatory components such as 
inflammatory bowel disease, atherosclerosis, Parkinson’s and Alzheimer’s diseases, multiple 
sclerosis, lupus, rheumatoid arthritis and CF [10,101–103]. 
 
2.3.4. Degradation 
The human body produces thousands of dollars’ worth of HA daily, however the action of 
HAses and ROS with aging and during diseases make its abundance and molecular weight 
decrease [2,3,9,104]. HAases were first termed as such in 1971 by Karl Meyer who also classified 
them in three distinct types based on biochemical analyses and generated end products. The first 
class constitutes a family of enzymes derived from animal venoms, urine, blood and sperm, among 
others. They are responsible for the fragmentation of HA of all sizes into short chains, down to 
tetra-saccharides. The second class of HAases has not been studied, however they are known as 
the leech HAases due to their presence in blood sucking organisms like leeches, bed bugs, ticks, 
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flies, mosquitoes and certain crustaceans. Microbial HAases are the third type and they decrease 
the permeability of the ECM to facilitate invasion of pathogens and spreading of toxins. Fungal 
HAases have not been characterized yet [67,105]. Higher levels of HAase expression and activity 
have been documented in many diseases. A type 1 HAase has been shown to have an important 
regulatory role in bladder cancer and increases in its relative abundance lead to increased tumor 
growth and proliferation [106,107]. There have also been indications that HAases are involved in 
the turnover of HA during early phases of lung injury and might play important roles in the 
pathogenesis of lung fibrosis [108]. Acute exacerbations of chronic obstructive pulmonary disease 
(COPD) are associated with increased HAase activity in BAL, which may contribute to airway 
inflammation and lung function decline [109]. 
 
The molecular weight of HA may be altered by oxidative damage [110]. The size of HA in 
cigarette smoke exposed mice is significantly smaller (70 kDa less in average) than HA of mice 
not exposed to smoke [111]. Several previous studies have reported hydroxides as the primary and 
sole species responsible for HA degradation [112–115]. Moreover, inhibition of ROS induced HA 
degradation was linked to a reduction of inflammation in bleomycin and asbestos-induced models 
of pulmonary fibrosis [116,117]. A murine model of allergic contact dermatitis demonstrated that 
an increased production of ROS is accompanied by HA breakdown to pro-inflammatory LMW 
fragments in the skin [118]. Other non-enzymatic reactions that may degrade HA (acidity, 
alkalinity, ultrasound and heat) have been reviewed in detail by Stern and others [119].  
 
2.3.5. Sources  
GAGs have a great variety of structures and biochemical features which vary depending 
on the source, type of tissue, age, physiological conditions and extraction methods, among others. 
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This variability makes GAG chains or fragments versatile to interact with many kinds of receptors 
and bioactive proteins. This heterogeneity however, complicates the reproducibility of yields and 
clinical effects. 
 
HMW-HA was extracted from fresh cattle vitreous humor in 1934 with a reported yield of 
0.25 g from 100 eyes [65]. Currently, a well-established source of HA is chicken combs. Severo 
da Rosa and others extracted 15 µg hexuronic acid/ mg dry tissue, which is equivalent to 
approximately 2.4 µg hexuronic acid/ mg wet chicken combs. The extraction of the total GAGs 
was conducted through acetone dehydration and choloroform: methanol delipidation followed by 
papain digestion and precipitation by a series of NaCl and ethanol washes [120]. These results 
from 42-day old animals are lower than the values reported by Nakano and others in rooster comb 
(4.0 µg uronic acid/ mg wet tissue) from 52-week old animals following a method in which 
samples were dehydrated with acetone prior to papain digestion, tricholoroacetic acid (TCA) 
deproteinization and dialysis [121]. Higher HA content values in rooster combs were also reported 
by Nakano and Sim in 1989 and the concentration was also estimated to be two-fold greater in the 
comb than in the wattle [122]. HA was also extracted from rooster combs by Kang and others 
using a method that aimed to reduce time and cost to accommodate a large-scale process. Frozen 
comb samples (500 g) were ground and defatted/dehydrated with acetone to yield 80 g of dry 
material that was extracted with sodium acetate and purified with ethanol followed by dialysis. 
Finally, the HA was precipitated with ethanol and heat treated to yield 1 µg dry HA/ mg wet tissue 
of an average molecular weight of 1200 kDa [123]. The rooster comb extraction process is facing 





Fish and fish eyeballs are also a valuable source of HA GAGs. Swordfish (Xiphias gladius) 
and shark (Prionace sp.) vitreous humor was decomposed and clarified by centrifugation before 
ultrafiltration, electrodeposition and alcoholic precipitation in a process optimized by Murado and 
others. The reported yields were 0.055 and 0.3 g HA/ Kg of vitreous humor in swordfish and shark, 
respectively. In the same study, HA concentrations for pig synovial fluid (0.5-6 g HA/ L) and pig 
vitreous humor (0.04 g HA/ Kg) were reported [124]. GAGs have also been isolated from haddock 
(Theragra chalcogramma) by papain digestion, TCA deproteinization, dialysis, and 
cetylpyridinium chloride (CPC) precipitation. The Fourier transform infrared spectroscopy (FT-
IR) absorption spectra of the purified haddock extracts fitted the main characteristics of GAGs and 
suggested the presence of CS and DS, but mainly HA [94]. Chicken (42 d old) keel cartilage has 
been reported to be a good source of CS following extraction with magnesium chloride. Results 
showed a yield of 33 mg GAGs/ g wet keel cartilage and 75.5% of the GAGs were CS with an 
average molecular weight of 48.5 kDa [125].  
 
Despite the abundance of animal sources of HA, currently the main production method is 
microbial fermentation due to lower costs and environmental impact. Microbial HA production on 
an industrial scale was first achieved by Shiseido Group (Tokyo, Japan) in the 1980’s and since 
then significant advances have been made to increase fermentation efficiency. Culture conditions 
(pH, temperature, culture media, agitation speed, shear stress, dissolved oxygen, bioreactor type) 
and batch modes (batch vs continuous) have been extensively studied to increase HA yields instead 
of promoting cell growth. Streptococcus sp. is the main producer, however the industry is facing 
issues due to its pathogenicity [33,104]. Recently, the production of HA by Streptococcus equi 
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subsp zooepidemicus in media formulated from fish by-products was investigated. The process 
yielded more than 2 g HA per liter with a molecular weight of 1730-1900 kDa and remarkable cost 
savings (>50% less than commercial media) [126]. Similarly, the yield of HA from the same 
bacterial strain using commercial media was 2.83 g/L with a protein content of 23.08% and average 
molecular weight of 538 kDa. The FT-IR spectrum showed the characteristic stretches of HA 
standards and excellent wound healing properties in a rat model [127]. 
 
Addressing the drawbacks of bacterial fermentation and animal sources, Novozymes 
(Copenhagen, Denmark) recently launched HA production by Bacillus subtilis using a water based 
process and a growth medium free of animal ingredients or toxins. Moreover, defined molecular 
weights can be produced [128]. Other bacteria used for recombinant HA production include 
Lactococcus lactis [129], Agrobacterium sp. [130], and E. coli [131] with yields of 0.65, 0.3 and 
2.0-3.8 g/L, respectively. Recombinant HA production yields are generally lower than bacterial 
fermentation yields. 
 
2.4. Cystic Fibrosis 
2.4.1. Introduction 
CF is a life-limiting condition that affects ~29,000 individuals in the United States and 
~70,000 worldwide with an estimated frequency of 1 in 2,500 births [30,132,133]. The disease 
affects primarily those of European descent, however it has been reported in all races and 
ethnicities [15]. It is an autosomal recessive disorder specifically related to abnormalities in the 
expression and function of the CFTR resulting in abnormal ion transport across epithelial surfaces 
in the sweat glands, gastrointestinal, reproductive and respiratory systems. The abnormal salt and 
water transport results in viscous secretions in the airways of the lungs and pancreas ducts, leading 
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to obstructions that cause inflammation, tissue damage and finally failure of the organ systems 
[15,134]. Achieving and maintaining an optimal nutrition status is a critical component of CF care 
[135], however obstructive lung disease is the primary cause of morbidity and is responsible for 
~80% of the mortality [15]. The median survival age has increased significantly from 33.4 years 
in 2003 to 40.7 years in 2013 [136] due to currently available therapies that address the CFTR 
defect consequences (pancreatic enzyme supplements, antibiotics, anti-inflammatory drugs and 
sputum thinners) or the CFTR basic defect (CFTR potentiators) [134,137].  
 
2.4.2. History of Cystic Fibrosis 
The first description of this disease in the United States was published by Dorothy 
Andersen, M.D. in 1938 as a pancreatic affection, however it was until 1951 that a connection was 
made between CF of the pancreas and widespread abnormality in epithelial salt transport [134]. In 
1953, Sant’Agnese and colleagues reported that Na+ and Cl- levels were markedly elevated in the 
sweat of CF patients and pointed towards a disturbance in the sweat glands [138], leading to the 
development of the sweat test as a reliable diagnostic test for CF in 1959 [139,140]. In the 1980’s, 
a number of studies supported the hypothesis that the disease’s basic defect altered Cl- permeability 
[141–143] and in 1989 the gene responsible for CF was cloned and called CFTR [144,145]. In the 
clinics, major advances in treating the symptoms and delaying disease progression have been made 
over the years, hence improving quality of life and increasing life expectancy. This is a result of a 
better understanding of the natural course of inflammation and infection which has resulted in 
strategies to assure prompt diagnosis, timely nutritional supplementation, early treatment of 
exacerbations and implementation of effective hygienic measures in and outside CF centers, 




2.4.3. The Cystic Fibrosis Transmembrane Conductance Regulator Protein 
CFTR is a member of the adenosine triphosphate (ATP)-binding cassette family of 
transporters, which use energy from ATP hydrolysis to pump substrates across cellular 
membranes. It is the major epithelial ion (Cl-) regulator located primarily in the apical plasma 
membrane, therefore it is key in transepithelial salt transport and fluid flow [137,147]. The amino 
acids of CFTR form five domains: two membrane spanning domains (MSD-1 & MSD-2), two 
nucleotide binding domains (NBD-1 & NBD-2) and a regulatory domain (RD). The opening of 
the anion pathway in CFTR requires phosphorylation of the channel by cyclic adenosine 
monophosphate-dependent protein kinase A (cAMP-PKA). Once the CTFR RD is phosphorylated, 
channel gating is regulated by ATP hydrolysis in the NBDs. The RD is dephosphorylated by 
protein phosphatases to return the channel to its inactive state (Figure 2.4) [134,139,147]. 
 
 




In addition to regulation of CTR function by nucleotide binding and phosphorylation, the amount 
and quality of CFTR production are also tightly regulated in the endoplasmic reticulum [148]. 
 
The CFTR is directly responsible for CF and a person must have two abnormal CFTR 
genes to manifest the disease. According to the CFTR Mutation Database 
(http://www.genet.sickkids.on.ca/), there are six classes of CFTR mutations which include 2,006 
different mutations [149] that result in a particular phenotype (Figure 2.5).  
 
 
Figure 2.5. Classification of CFTR mutations [150].  
 
The F508del mutation is associated with severe CF and it is the most common mutation 
occurring in ~86.4% of patients in one or both alleles. This is a class II mutation in which the 
CFTR protein is created but misfolded, keeping it from reaching the cell surface, specifically due 
to a phenylalanine residue deletion in the 508 position [145]. Other CFTR mutation classes include 
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nonsense mutations (Class I), altered gating mutations despite expression of full length protein 
(Class III), misense mutations resulting in lowered Cl- permeability (Class IV), insufficient 
synthesis of CFTR (Class V) and reduced CFTR half-life in the apical membrane mutations (Class 
VI) [133,134,150]. These dysfunctions in the CFTR disrupt ion transport in the epithelia of various 
organs which results in the many manifestations of the disease, from airway disease and pancreatic 
failure to male infertility and elevated electrolyte levels in sweat [138,151–153].  
 
In addition to its role in Cl- transport, the CFTR in its active state negatively regulates the 
epithelial Na+ channel (ENaC). Since Cl- conductance is defective in CF, ENaC currents are not 
inhibited resulting in increased Na+ absorption in the airway epithelium and depletion of the airway 
surface liquid (ASL) which is known as the “low-volume hypothesis” [154–157] (Figure 2.6). 
 
 





Nationwide newborn screening for CF has been in place since 2010 and even earlier in 
some states. As a result, a growing proportion of people are now diagnosed in infancy and in 2014, 
63.7% of new diagnoses were detected within the first year of life and often before the onset of 
symptoms [133,136]. There is consensus that CF is diagnosed based on evidence of CFTR 
abnormality (sweat test or genotyping) and characteristic phenotypic features or family history. 
There has been a decrease in the use of sweat electrolyte testing due to an increased reliance on 
genetic testing, however the challenges of using genetic analysis alone are that it does not provide 
information about the gene product or function and all of the mutations might not be identified 
[139,159,160]. Early diagnosis and treatment have led to better lung function and nutritional 
outcomes later in life, however the disease continues to be characterized by a number of life 
threatening symptoms. 
 
2.4.5. Airway Pathophysiology in Cystic Fibrosis  
Abnormal CFTR expression in the human bronchus affects predominantly the submucosal 
glands. [161,162]. Clinicians often describe CF as a vicious cycle of airway inflammation, 
obstruction and infection in which each of these components contributes to the progression of the 
lung disease [163]. The main cause of death is due to chronic inflammation and persistent 
infections with Pseudomonas aeruginosa and other pathogens. This section focuses only on the 
pulmonary aspects of this genetic disease and does not include other important aspects of this 
illness including gastrointestinal, endocrine and metabolic manifestations.  
 
CF leads to severe pathological changes in the airway epithelium as it induces an early, 
intense and constitutive inflammatory process even before the onset of bacterial infection [21]. 
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This congenital pro-inflammatory phenotype is caused by an innate increase in ROS promoted by 
misfolded protein stress and TGAse-driven defective autophagy of misfolded or damaged CFTR 
aggresomes [164–166]. It has also been demonstrated in human CF epithelial cell lines and in adult 
CF mice (F508del) that TGAse is a driver of inflammation in CF airways and it can be upregulated 
by ROS [29]. This inflammatory process leads to the increased expression of NF-κβ and pro-
inflammatory cytokines as well as a large recruitment of neutrophils [17–20]. Moreover, the 
excessive production of the serine protease NE, overwhelms the normal anti-proteinase capacity 
and results in irreversible airway structural damage which overwhelms the normal repair pathways 
[167,168]. Although NE’s physiological role is to degrade phagocytosed proteins, it also degrades 
structural proteins like elastin, collagen, fibronectin and proteoglycans causing damage to the 
airway epithelia [169,170] and contributing to bronchiectasis progression. NE is also the most 
significant predictor of bronchiectasis in early-life CF [171]. It has been reported that neutrophils 
from CF patients release significantly more ROS that neutrophils from healthy individuals [172], 
thus further perpetuating the inflammatory response. Furthermore, the lysis of neutrophils results 
in large amounts of DNA that contribute to the increased viscosity and adhesiveness of lung 
secretions and formation of mucous plugs [173]. 
 
The airway tissue damage and the ion transport defects in CF epithelia cause deficiencies 
in mucociliary clearance (MCC) that result in airway obstruction. Sodium hyper-absorption and 
defective chloride secretion drive increased water absorption by osmosis which reduces mucus 
clearance and increases mucus adherence resulting in a reduced ASL height [158]. The ASL 
consists of two layers above the epithelial surface: a mucus layer and a perciliary liquid layer [174] 
and it has been suggested in mouse, human and in vitro studies that its hydration status predicts 
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the outcome of therapeutic interventions [156,175,176]. Understanding of this pathological 
condition is critical as MCC is recognized as the primary physiologic defense mechanism and it is 
used as an outcome measure in the development of new physical and pharmacological therapies 
for patients with CF. Moreover, for normal MCC to occur it is necessary that the airway epithelial 
cells are intact [177] and as discussed previously this is compromised in CF airways due to the 
exaggerated expression of NE. It has been demonstrated in vitro that mucus transport is lost within 
24 h in CF cultures, compared to up to 72 h in normal airways, mainly as a result of increased 
absorption of liquid from the culture surface [178]. A study in mice with airway-specific 
overexpression of ENaC, demonstrated that the lungs are normal at birth, however there is an early 
surface dehydration, increased mucus concentration and increased mucus adhesion that produce 
mucus plugging which triggers airway inflammation and is associated with early mortality [179]. 
In humans, large volumes of viscous mucopurulent sputum are accumulated putting patients at a 
higher risk of developing lung infections [180]. A long term clinical study measured a significant 
reduction in pulmonary exacerbations, compared to a control group, upon the administration of 
hypertonic saline solution twice daily during 48 weeks (4 ml of 7% saline) [181]. Likewise, 
Donaldson and others reported an improvement in MCC after a 14-day saline treatment (5 ml of 
7% saline) four times daily. Despite improvement in treatments, decreased lung function and 
COPD have been and continue to be the leading cause of CF morbidity and mortality [182–184].  
 
Along with obstructive pulmonary disease, chronic infections represent a serious problem 
for most individuals with CF and it is considered a paradox that the large numbers of neutrophils 
present in the CF airways fail to effectively kill colonizing bacteria [167]. Bactericidal activity has 
been reported in CF epithelia at low NaCl concentrations, however the CF ASL has a high NaCl 
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concentration which reduces bactericidal activity [151]. More recently, Pezzulo and others (2012) 
showed that the lack of CFTR reduces bacterial killing in newborn pigs and in primary epithelial 
cultures. This result was linked to a lower ASL pH in CF pigs compared to their wild-type 
counterparts and further linked to a HCO3
- transport deficiency. CFTR facilitates HCO3
- secretion, 
therefore its absence or malfunction causes the ASL pH to fall which inhibits antimicrobial 
function, reduces MCC and finally facilitates bacterial colonization [185,186]. Similarly, Nordin 
and others (2013) investigated the expression pattern and activity of the antibacterial growth factor 
midkine in CF lung tissue. Midkine was present at 100-fold higher levels in CF sputum when 
compared with sputum from healthy control subjects, however it was subject to increased 
degradation into smaller fractions by NE which impaired its bactericidal properties against P. 
aeruginosa. Increased salt and acidity also impaired its bactericidal properties in vitro [187]. 
 
Bacterial infections in CF frequently have an age-dependent sequence (Figure 2.7). In 
2014, the CF Foundation reported that early infections are most frequently caused by 
Staphylococcus aureus, P. aeruginosa and Haemophilus influenzae, however P. aeruginosa is by 
far the most significant pathogen throughout the life of CF patients [133,188]. There is evidence 
indicating that in young children with CF, early P. aeruginosa infection gradually declines lung 
function and increases the risk of morbidity and mortality [189,190]. Additionally, Aaron and 
others (2015) constructed a statistical model to assess the 1-year risk of death for CF patients using 
data from 1970 up to 2010 and concluded that having Pseudomonas plays a critical role especially 
when a patient’s overall health is moderately to severely compromised [191]. Even though the 
prevalence of P. aeruginosa continues to decrease due to prevention of initial infection, there is 
still a prevalence of multi-drug resistant P. aeruginosa (18.1% of CF patients in 2014). A five-fold 
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increase in prevalence of methicillin resistant S. aureus has also been reported which becomes 
critical as S. aureus isolation has been proposed as a risk factor for initial P. aeruginosa infection 
in young CF patients [192]. 
 
Figure 2.7. Prevalence of Respiratory Microorganisms by Age Cohort, 2014 [133].  
 
In CF patients P. aeruginosa has demonstrated a very high level of adaptation and 
mutability to establish a persistent infection, likely caused by the large diversity of infecting 
organisms, ineffective host defenses and ongoing antibiotic therapies [188,193,194]. Among the 
organisms identified later in the course of CF disease are: the Burkholderia cepacia complex, 
Strenotrophomonas maltophilia, Achromobacter, Aspergillus and other non-tuberculous 
mycobacteria [195–200]. Of these, the B. cepacia complex is the most dangerous because of its 
rapid progression to death through high fevers and bacteremia [188]. 
 
2.4.6. Current Treatment  
Current CF clinical practice guidelines recommend individuals ages 6 and older to visit 
care centers at least four times per year to conduct microbiological cultures, perform pulmonary 
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function tests, receive an influenza vaccine, measure liver enzyme levels and blood levels of fat-
soluble vitamins [136]. CF is a disease that requires more intensive treatments as the disease 
progresses, therefore the availability of multiple pulmonary therapies is beneficial. Typically, 
chronic pulmonary therapies with dornase alfa, hypertonic saline, ibuprofen and/or tobramycin, 
among others, are a major component of the treatment regime [133,201,202] (Figure 2.8). DeWitt 
and others (2008) estimated the United States mean annual cost of care for patients with CF with 
mild impairment in lung function to be over $43,000. These costs are driven by medications, but 
also include hospitalization costs, emergency room and home nursing visits and indirect costs 
associated with missed school or work days [203]. More recently, similar costs (€26,335 - €76,271) 
were reported for patients in the United Kingdom depending on the severity of the disease [204]. 
 
 
Figure 2.8. Chronic Medication Use in CF Patients, 1995-2014 [133].  
 
Dornase alpha is an orphan drug described as a recombinant human deoxyribonuclease 
(DNase) that hydrolyzes DNA present in the sputum of CF patients, reducing the lung viscosity 
and improving MCC [205,206]. The nebulized use of this DNase is prescribed for the majority of 
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the population and more than half is prescribed hypertonic saline either in place of, or in addition 
to dornase alpha [133]. In a multicenter study of 48 CF patients, 18 months treatment (2.5 mg/day) 
with dornase alpha reduced DNA load in BAL [207]. A 3-year multicenter study with 105 patients 
reported on the positive influence of dornase alpha on airway inflammation. It was shown that 
neutrophil content, NE activity and IL-8 remained stable in patients treated with DNase compared 
to control and untreated subjects [208]. Two week dornase alpha treatment has also been shown 
to improve forced expiratory volume in 1 second (FEV1) in 67% of patients independently of 
weight, age or baseline FEV1 [205]. More recently, it was reported that DNase treatment (25 µl of 
1 mg/ml) in mice eliminates lung neutrophil extracellular traps and improves lung mechanics, 
however it does not prevent airway inflammation [209]. 
 
Hypertonic saline (HTS) is also available to CF patients as a means to restore ASL. HTS 
is defined as a solution possessing an osmotic pressure greater than that of physiologic isotonic 
NaCl solution (0.9%) and popularity of its use has increased on the basis of a number of studies 
[210]. Inhalation of HTS has been reported to increase airway antioxidant levels, improve MCC, 
increase ASL hydration, and inhibit ENaC, among other positive effects. In a study on adult CFTR 
knockout mice, nebulized 7% sterile HTS (2 mL/mouse) promoted an increase in glutathione, an 
airway antioxidant that can protect the airways from hypochlorous acid mediated injury [211]. A 
long term (48 weeks) clinical study with 164 CF patients showed that patients treated with 7% 
HTS (4 ml twice daily) had significantly higher forced vital capacity (FVC) and FEV1, as well as 
fewer pulmonary exacerbations than control patients. Furthermore, significant improvements in 
quality of life were observed [181]. HTS at a concentration of 3% or higher is used to create an 
osmotic gradient that draws water into the airway surface, therefore improving ASL and 
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facilitating MCC [212]. The findings of a human study by Hebestreit and others indicate a 
significant inhibition of luminal sodium conductance by HTS which may be associated with 
improved fluid transport across the respiratory epithelium, improved MCC and increased lung 
function [213]. There is also increasing evidence suggesting that HTS is beneficial through its anti-
inflammatory properties due to reduction of IL-8 concentrations and neutrophil chemotaxis in CF 
airways [210]. Moreover, HTS has the ability to reduce bacterial activity and biofilm formation 
[214,215]. Finally, the tolerability and pleasantness of 7% HTS can be significantly improved 
when administered together with 0.1% HA, thus improving adherence to HTS therapy due to 
reduced cough, throat irritation and saltiness [24,32].  
 
Symptomatic therapies to treat CF patients include non-chronic use of high-dose ibuprofen 
(25-30 mg/kg) [133,216]. Ibuprofen administered twice daily for four years (50-100 µg/ml in 
plasma) to CF patients (5-39 years old) with mild lung disease resulted in a slower annual rate of 
change in FEV1 compared to patients assigned to placebo [217]. Similarly, a long term clinical 
study with children and adolescents with CF concluded that ibuprofen treatment significantly 
slowed the rates of FEV1 decline compared to untreated subjects [218]. In both studies the side 
effects were not serious or the apparent benefits of ibuprofen therapy outweighed the small risks. 
Despite its apparent benefits, ibuprofen is infrequently used due to the need to measure plasma 
levels and because of the potential renal and gastrointestinal side effects [146].  
 
Anti-infective pulmonary therapies with inhaled tobramycin, inhaled aztreonam or 
azithromycin are also widely used in 69.8%, 42.5% and 67.5%, respectively, of CF patients (≥ 6 
years) infected with P. aeruginosa [133]. Tobramycin is the established standard of antibiotic care 
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in CF. It is an aminoglycoside antibiotic that has shown a sustained improvement in FEV1 upon 
chronic inhaled administration over 2 years [219]. In a multicenter study of 520 patients, 
intermittent administration of inhaled tobramycin for 6 months showed significant improvement 
in lung function after two weeks and the effects were maintained throughout the study [220]. 
Tobramycin exerts its antimicrobial activity by binding to the bacterial ribosome and inhibiting 
protein synthesis, thus inhibiting growth and division of the bacteria [221]. A recent study showed 
that the combination therapy of HA plus tobramycin is effective in the treatment of bacterial 
rhinosinusitis in CF [31]. Long-term treatment with azithromycin is also included in the current 
guidelines for CF patients older than 6 years. Although it is not active against P. aeruginosa, 
azithromycin can interfere in some bacterial activities and make them more susceptible to 
antibiotic treatment [222]. Aztreonam was recently approved (2010) for the treatment of CF and 
an aztreonam vs tobramycin comparative study demonstrated that aztreonam patients had fewer 
respiratory hospitalizations [223]. Early anti P. aeruginosa antibiotics have been demonstrated to 
successfully prevent chronic infection and improve clinical outcomes, however there is still debate 
on the side effects of long term treatment, most importantly the development of antibiotic 
resistance in airway pathogens. 
 
GAGs have been investigated as potential molecules for the treatment of CF and airway 
disease symptoms due to their water-retaining, re-epithelizing and anti-inflammatory properties, 
among others. Nebulized 300-500 kDa HA (0.5 mg HA/animal/day for 7 days) was effective in 
controlling inflammation in vivo in mice CF airways as well as in vitro in human airway epithelial 
cells (100 µg HA/ml for 24 h) [10]. Adult sheep treated with nebulized 150 kDa or 300 kDa HA 
(3-15 mg/ewe), dose dependently improved their pulmonary resistance after challenge with human 
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NE [11]. Moreover, seven days after treatment of cultured ovine tracheal cells with HA, ciliary 
beat frequency increased by 16% which may be indicative of the late expression of an HA-binding 
receptor in this particular culture [224]. Researchers have also proposed the pivotal role of HA in 
mucosal host defense by stimulating ciliary beating through its interaction with ciliary RHAMM 
[79]. Finally, intranasal use of sodium hyaluronate (9 mg twice daily for 30 days) in patients 
undergoing functional endoscopic sinus surgery for nasal polyposis significantly improved MCC 
and other important clinical parameters [225].  
 
The anti-inflammatory and tissue regeneration properties of sulfated GAGs have been 
reviewed in various diseases, however the results have not been promising in relation to 
symptomatic treatment of CF. For example, a pilot clinical study demonstrated no evidence of 
improved FEV1, MCC or inflammation markers with a dose of 50,000 IU of heparin twice daily 
for two weeks [226]. Furthermore, it has been shown that high expression of CS and HS in normal 
and CF human lung tissue, facilitate the binding of IL-8 protecting it from proteolysis and 
prolonging its activity [227,228].  
 
2.4.7. Markers of Inflammation in Cystic Fibrosis 
Dysregulated inflammation is an early event in CF and it has a direct link to defective 
CFTR. The CFTR mutations lead to an increase in TGAse levels and activity which result in the 
cross-linking and proteasome degradation of the peroxisome proliferator-activated receptor-
(PPAR), a key negative regulator of inflammatory gene expression [30]. This defect perturbs 
the regulation of the NF-κβ pathway causing excessive production of inflammatory mediators 
[229]. It has also been shown that the most characteristic feature of airway inflammation in CF is 
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a persistent influx of neutrophils and an increased NE burden, driven by host and bacterial chemo-
attractants [16,230]. IL-8 is the major neutrophil chemo-attractant and its levels are elevated in the 
BAL, sputum and serum of CF patients [231–233]. In healthy tissues, IL-8 is barely detectable, 
but it is rapidly increased in response to pro-inflammatory cytokines, P. aeruginosa or cellular 
stress [234,235]. Increased concentrations of other pro-inflammatory cytokines, such as IL-1β, 
TNF-α and IL-6 have also been detected in CF airways [236–238]. Furthermore, the high NE load 
in CF airways has been hypothesized to trigger the senescence of epithelial cells which can be in 
a pro-inflammatory state. Three different senescence biomarkers were shown to be increased in 
CF airways compared to control subjects, therefore contributing to the perpetuation of chronic 
inflammation [239]. Most research focuses on increased activation of inflammatory responses, 
however there is also an inability to resolve inflammation due to deficiencies in the expression of 
anti-inflammatory molecules including interleukin-10 (IL-10), nitric oxide and lipoin-A4 [240]. 
IL-10 is not thought to be under direct control of NF-kB, however it terminates acute inflammatory 
responses, downregulates production of TNF-α, IL-6, IL-1β and IL-8 by macrophages, inhibits 












MATERIALS AND METHODS 
 
3.1. Experimental Design and Statistical Analysis 
A completely randomized block design (CRBD), with three GAG extractions (repetitions) 
as the blocking units, was used to test equality of means among treatments. The null (Ho: µ1 = µ2 
= µ3 = µ4) and alternate (Ha: some µi is different) hypotheses were stated and all experiments and 
analyses were conducted in triplicates. Analyses of variance (ANOVA) using Proc GLM were 
conducted along with post-ANOVA Tukey pairwise tests using the Statistical Analysis System 
(SAS®) version 9.4 Results were reported as means ± standard deviations (SD) and differences 
were considered significant at p≤0.05.  
 
The gene expression analysis experiments were carried out in triplicate and statistical 
analysis was performed using the SABiosciences PCR Array Data Analysis Web-based software 
which calculated fold-regulation p-values using a Student’s t-test on the fold-change values for 
each gene in the treatment group compared to the control group (p≤0.05). ANOVA and post-
ANOVA Tukey pairwise tests using the Statistical Analysis System (SAS®) version 9.4 were 
conducted to evaluate RNA purity and PCR control gene expression. Results are presented as 
means ± standard error (SE) (p≤0.05). 
 
3.2. Materials 
Butyl alcohol (Cat. No. W217820), 2-mercaptoethanol (Cat. No. M-7154), absolute etanol 
for molecular biology (Cat. No. E7023), porcine pepsin (Cat. No. P7125), L-cysteine (Cat. No. 
W326305), ethylenediaminetetraacetic acid (EDTA) (Cat. No. E9884), sodium chloride (Cat. No. 
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793566), crystalline carbazole (Cat. No. C5132), sodium tetraborate decahydrate (Cat. No. 
B9876), HAase type 1 from bovine testes (607 U/mg) (Cat. No. H3506), ChrAse ABC from 
Proteus vulgaris (Cat. No. C3667), CS-A from bovine trachea (Cat. No. C9819), Stains-All 95% 
(Cat. No. E9379), gel loading buffer (Cat. No. G2526), single use micro DispoDialyzers™ (50 
kDa molecular weight cut-off (MWCO)) (Cat. No. D9187) and dialysis cellulose tubing (14 kDa 
MWCO) (Cat. No. D9402) were purchased from Sigma Aldrich (St. Louis, MO). Absolute ethanol 
200 proof (Cat. No. 111000200) was purchased from VWR (Radnor, PA). Sodium hydroxide (Cat. 
No. S318-3), acetic acid (Cat. No. UN2789), urea peroxide (Cat. No. ACS241020010), EMD 
Millipore ACS grade sulfuric acid (Cat. No. MSX1244PC5), hydrochloric acid (HCl) ACS grade 
(Cat. No. S25838), monobasic anhydrous sodium acetate (Cat. No. BP3331), Invitrogen™ 
Novex™ sharp pre-stained protein standard (Cat. No. LC5800) and HA standard from 
Streptococcus sp. (94%) (Cat. No. AC251770010) were obtained from Fisher Scientific 
(Pittsburgh, PA). Papain (Cat. No. 102566) was acquired from MP Biomedicals (Santa Ana, CA). 
UltraPure™ agarose (Cat. No. 16500500) and tris borate-EDTA (TBE) buffer (Cat. No. 15581044) 
were obtained from Thermo Fisher Scientific (Waltham, MA). Select-HA™ low polydispersity 
HA standards HiLadder (1648, 1138, 940, 667, 509 kDa) and LoLadder (509, 310, 213, 111, 30.2) 
(Cat. No. HYA-HILAD-20 and HYA-LOLAD-20) were purchased from Hyalose (Oklahoma City, 
OK). Bovine serum albumin (BSA) (Cat. No. SC-2323) was purchased from Santa Cruz 
Biotechnologies Inc. (Dallas, TX). Sodium phosphate (Cat. No. 0571), sucrose (Cat. No. 0335), 
and ultrapure grade Tris-HCl (Cat. No. 0234) from Amresco (Solon, OH).  
 
For the CF ex-vivo mice study retinoic acid (Cat. No. R2625), insulin (Cat. No. 91077c), 
transferrin (Cat. No. T8158), cholera toxin (Cat. No. C8052), bovine pituitary extract (Cat. No. 
39 
 
P1476), pronase from Streptomyces griseus (Cat. No. 10165921001) and DNase 1 from bovine 
pancreas (Cat. No. DN25) were purchased from Sigma Aldrich (St. Louis, MO). Corning™ Nu-
Serum growth medium supplement (Cat. No. CB-51000), Y-27632 ROCK inhibitor (Cat. No. 
BDB562822), rat tail collagen I (Cat. No. CB-354249), Corning™ fetal bovine serum (FBS) (Cat. 
No. 11648647), methyl sulfoxide (>99.8%) (Cat. No. AC327182500), phosphate buffered saline 
solution (pH 7.4) (Cat. No. 10010031), recombinant mouse epidermal growth factor (Cat. No. 
PMG8041), Dulbecco’s Modified Eagle Medium (DMEM)/Ham’s F-12 (1:1) (HEPES) (Cat. No. 
11330-032), Gibco™ penicillin-streptomycin (10,000 U/ml; 10,000 mg/ml) (Cat. No.15-140-122), 
Corning™ Primaria™ tissue culture dishes (Cat. No. 08-772-4A), Corning™ Costar™ Transwell™ 
clear polyester membrane inserts for 12-well plates (Cat. No. 07-200-161) and Falcon™ 6-well 
tissue culture plates (Cat. No. 0877233) were obtained from Fisher Scientific (Pittsburgh, PA).  
 
3.3. Extraction of GAGs from Alligator Carcasses, Feet and Backstraps 
Farmed AFT (2 anterior & 2 posterior) and ABS were collected from Vermilion Gator 
Farm Inc. in Abbeville, Louisiana and waste ACS were provided by Jacques’ Croc’s and Farm 
Pride (Scott, LA). All animals were between 12 and 18 months old at the time of slaughter and 
samples were kept at -20◦C until used for GAG extraction at the Louisiana State University School 
of Nutrition and Food Science (Baton Rouge, LA).  
 
A Baader® 693 bone separator (Indianola, MS) was used to process ACS and separate 
bones from meat. Three passes through a perforated stainless steel drum (Ø = 3 mm) were 
performed at increasing belt pressures (20, 30 and 40 bar). Only bones including connective tissue 
were used for GAG extraction from ACS. AFT and ABS were ground in a Hobart HCM450 
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grinder-mixer (Troy, OH) prior to GAG extraction. The extraction process (Figure 3.1) was 
developed by adapting methods previously reported by Ogawa and others [242], Losso and others 
[243], Kittiphattanabawon and others [244], Severo da Rosa and others [120] and 
Garnjanagoonchorn and others [245]. To remove non-collagenous proteins and bleach skin 
pigments, the ACS, AFT or ABS were mixed with 0.2N NaOH at a sample: solution ratio of 1: 2.5 
(w/v), in addition to 0.5% (w/w) urea peroxide. The mixture was stirred intermittently for 12 h 
with a solution change after 6 h. The deproteinized samples were defatted with 20% butyl alcohol 
(1:2.5 w/v) for 3 h and for removal of inorganic compounds samples were soaked in a 0.2N HCl 
solution (1:2.5 w/v) for 3 h with manual stirring once every hour. Samples were filtered through 
cheese cloth and washed in running tap water after every step. For collagen proteolysis, the 
deproteinized, defatted and demineralized samples were finely ground with 1M acetic acid (1:2 
w/v) and mixed with pepsin (0.3% w/w). Pepsin proteolysis was conducted for 4 h at 40°C, 
followed by addition of papain (0.3% w/w) for 12 h at 60°C. Prior to use, papain was activated in 
1:1 (w/v) digestion buffer (100 mM Na acetate, 5 mM L-cysteine, 5 mM EDTA). A double layer 
of cheesecloth was used to filter the resulting clear solution and the filtrate was collected, 
centrifuged (7,000 rpm/ 20 min/ 20°C) and filtered again using filter paper (Whatman No. 4). 
Samples were dialyzed at 4°C using a 14 kDa MWCO cellulose membrane against distilled water 
for 24 h, with solution changes every 8 h. The dialyzed samples were mixed (1:1 v/v) with a 
solution composed of 2M NaCl: absolute ethanol (5:1). Absolute ethanol was added (1:2 v/v) and 
GAGs were precipitated for 12 h at -20°C. The pellet was dissolved in distilled water prior to a 
heat treatment (90°C/ 5 min) to inactivate enzymes and disinfect samples. Finally, samples were 




































Figure 3.1. Process diagram of GAG extraction from alligator ACS, AFT and ABS. 
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Genesis 35XL pilot lyophilizer (Stone Ridge, NY) during 24 hours. Dry samples (< 5.0% 
moisture content) were stored at -80°C until analyzed. 
 
3.4. Extraction of GAGs from Alligator Eyeballs 
Farmed AEB were manually collected from heads at Vermilion Gator Farm Inc. in 
Abbeville, Louisiana. Alligator eyeball GAGs were obtained as reported by Murado and others 
with modifications [124]. AEB were cut vertically in half using a sharp scalpel blade to extract the 
vitreous humor (Figure 3.2). Subsequently, the vitreous humor was dissolved in distilled water 
(1:1 v/v) and homogenized in order to deconstruct it. Subsequently, the humor was clarified by 
centrifugation at 7,000 rpm (20 min / 4 °C). Two clear phases were obtained: dark sediment of 
impurities and a majority of vitreous humor supernatant. The supernatant was collected and protein  
 
 
Figure 3.2 Process diagram of GAG extraction from AEB. 
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hydrolyzed using papain in digestion buffer as described previously. Samples were dialyzed at 4°C 
using a 14 kDa MWCO membrane against distilled water for 24 h, with solution changes every 8 
h. Finally, the samples were heat-treated (90 °C/ 5 min) and stored at -80°C until used. 
 
3.5. Determination of Sulfated GAGs, HA and Total GAGs Content 
The content of sulfated GAGs was determined using a Chondrex Inc. (Redmond, WA) 
dimethylmethylene blue (DMB) assay (Cat. No. 6022) as reported by Garnjanagoonchorn and 
others [245]. Calibration curves were developed using a chondroitin-6-sulfate standard and 
samples were solubilized and diluted with PBS to fit the standard range. One hundred microliters 
of standards, samples and sample blanks were added in triplicates to a 96-well plate. Subsequently, 
a 1,9-DMB solution (100 µl) was added into the standard and sample wells, while PBS (100 µl) 
was added into the sample blanks. The plate absorbance was read at 525 nm within 5 min of DMB 
addition in a Bio-Rad Benchmark Plus Microplate Spectrophotometer (Philadelphia, PA). The 
content of sulfated GAGs was calculated by regression analysis. HA content was measured using 
an Echelon® competitive ELISA kit (50-1600 ng/ml) (K-1200, Echelon Biosciences Inc., Salt Lake 
City, UT) which detected molecules as small as 6.4 kDa. Manufacturer protocol instructions were 
followed. Briefly, 100 µl of HA standards and diluted samples were added into a 96-well 
incubation plate followed by 50 µl of detection solution, prior to incubation for 1 h at 37◦C. 
Following the incubation step, samples (100 µl) were transferred into a detection plate for 
competitive binding at 4◦C for 30 min. The plate was then washed three times with 200 µl PBS-
Tween (PBST), before addition of an enzyme-linked antibody and substrate solution. Colorimetric 
detection at 405 nm was used to detect the enzyme-substrate system comprised of alkaline 
phosphatase/ pNPP phosphatase substrate. The colorimetric signal was inversely proportional to 
the HA content in the sample and the concentration. A standard curve with the known amounts of 
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HA was used to determine concentration of HA. The total GAG content of the extracted materials 
was calculated by addition of the two analyses described above and further confirmed using a 
carbazole reaction to measure uronic acid after hydrolysis of GAGs with sulfuric acid, as 
previously reported [246–248]. The absorbance of samples was measured at 550 nm and GAG 
content was calculated by regression analysis using a HA sodium salt standard curve.  
 
3.6. GAGs Size Analysis 
The molecular weight of GAGs was evaluated by agarose gel electrophoresis based on the 
method of Cowman and others with modifications [249]. Agarose gels (0.75% w/v) were prepared 
by dissolving 0.3 g of agarose in 36 ml of water using 1.5 min of heating in a microwave oven. 
The agarose solution was cooled under running tap water for 3 min and then mixed with 4 ml of 
10X TBE buffer to make the final gel volume of 40 ml. Gels of 10 x 6.2 cm were cast in a casting 
accessory using an 8-tooth well-forming comb. Before electrophoresis, gels were allowed to set 
for at least 1 h. To load samples, the comb was removed and the gel plate was transferred to a Bio-
Rad (Hercules, CA) Mini-Sub® Cell GT system which was filled with 290 ml of pre-chilled 1X 
TBE buffer. Cells were loaded with samples (3 ug GAGs/ well in ultrapure water) and GAG 
standards (HA & CS) which were mixed with 4 µl of 2 M sucrose loading buffer and sample 
volume made up to 24 µl with ultrapure water. Select-HA™ HiLadder (5 µl) and LoLadder (5 µl) 
were mixed with deionized water (10 µl) and loading buffer (4 µl) before being loaded into a well. 
Electrophoresis was carried out at room temperature at a constant voltage of 70 V for 2.5 h using 
a Bio-Rad PowerPac™ power supply. The loading buffer tracking dye migrated about 80% of the 
gel during this time period. Immediately after the run the gel was placed in approximately 250 ml 
of a staining solution containing 0.005% Stains-All in 50% absolute ethanol (stored protected from 
light). The gel was stained overnight under light-protective cover at room temperature. For 
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destaining, the gel was transferred to a 10% ethanol solution and stored in the dark for 8 h with at 
least one change of destaining solution. Final destaining of any residual background was 
accomplished by placing the gel on a light box for a few minutes.  
 
Agarose gel electrophoresis was also performed on all samples after an alternative final 
dialysis step using single use micro DispoDialyzers™. Briefly, GAG dry samples were dissolved 
in distilled and deionized water (100 µl) and placed in a floating sample chamber that separated 
the low molecular weight GAGs (<50 kDa) through a cellulose membrane and into the dialysis 
buffer (tap water). Samples were dialyzed with constant stirring for 48 h in 200 ml of buffer with 
changes every 2, 5, 15, 30 and 45 h. Samples were recovered into a micro centrifuge tube by 
centrifugation (1-2 s) at 1500 rpm. Electrophoresis was performed as described above. 
 
3.7. Digestion of GAGs by Type-1 Hyaluronidase and Chondroitinase ABC 
Digestion of ACS, AFT, ABS and AEB samples by a type 1 bovine testes HAase was 
conducted to prove that the stains seen on the previously described agarose gels were truly GAGs. 
Phosphate Buffer (300 mM sodium phosphate, pH 5.35 at 37°C) was used to prepare a 0.5 mg/ml 
GAG solution which was completely dissolved and kept at 37°C in a water bath. Immediately 
before use, a 24,000 U/ml HAase stock solution was prepared by dissolving the enzyme in enzyme 
diluent (20 mM sodium phosphate with 77 mM sodium chloride and 0.01% (w/v) BSA, pH 7.0 at 
37°C). Ultrapure water was used and pH was adjusted with 1 N NaOH or 1 N HCl. The stock 
solution was diluted with enzyme diluent to obtain additional working solutions of 12,000 U and 
6,000 U. The final HAase assay concentrations (48, 24 and 12 U/µg sample) were obtained by 
mixing 0.5 ml of each GAG solution with 0.5 ml of enzyme solution (24,000, 12,000 or 6,000 
U/ml). Incubation was conducted at 37°C with continuous swirling during exactly 20 hours. HAase 
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was heat inactivated on a boiling water bath for 10 minutes prior to centrifugation at 10,000 rpm 
for another 10 min. Supernatants were collected and stored at -80°C until used. 
 
An enzymatic assay using ChrAse ABC was conducted on ACS GAGs to further confirm 
the identity of the purple stains in agarose gels stained with 0.005% Stains-All solution. A GAG 
solution in sample diluent (250 mM Tris-HCl and 300 mM sodium acetate with 0.05% (w/v) BSA, 
pH 8.0 at 37°C) and a ChrAse ABC solution (0.4 U/ml) in 0.01% BSA were prepared. Working 
enzyme solutions (0.2 U/ml and 0.1 U/ml) were prepared from dilutions of the stock solution. The 
final ChrAse assay concentrations (0.2, 0.1 and 0.05 U) were obtained by mixing equal parts of 
ACS sample solution and enzyme stock or working solutions. Digestion was conducted at 37°C 
during 8 h with constant swirling, after which samples were boiled for 10 min, centrifuged at 
10,000 rpm during 10 min and stored at -80°C until used. The results of the HAase and ChrAse 
ABC assays were evaluated by running all samples in 0.75% agarose gels and staining with 
0.005% Stains-All as described previously. 
 
3.8. Determination of Protein and Mineral Content 
Protein content of the solubilized purified GAG extracts was quantified by measuring 
absorbance at 562 nm using a Pierce™ Bicinchoninic Acid (BCA) Protein Assay (Philadelphia, 
PA). A series of dilutions of known concentrations of bovine serum albumin were used as 
standards and assayed alongside the GAG samples. GAG extract samples were prepared for 
mineral content by dilution of 100 mg in deionized water (10 ml) and filtration through a 0.22 µm 
syringe filter. Concentration determination of the filtered samples was carried out using 
inductively coupled plasma atomic emission spectrometry (ICP-AES) at the Louisiana State 
University Soil Testing and Plant Analysis Laboratory. 
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3.9. Structure Characterization by FT-IR Spectroscopy  
A Bruker (Billerica, MA) Tensor 27 FT-IR spectrometer with a MIRacle™ single 
reflection diamond/ZnSe attenuated total reflectance cell (Pike Technologies, Madison, WI) was 
employed to obtain FT-IR spectra of lyophilized ACS, AFT, ABS and AEB GAGs. Commercial 
HA and chondroitin-4-sulfate powders were analyzed and used as standard spectra. The spectrum 
of each compacted dry sample was obtained over 50 scans in the range of 650-4000 cm-1, against 
a background spectrum recorded from the clean empty cell at room temperature. Spectral data 
analysis was conducted using the OPUS data collection software version 7.2 (Bruker, Ettlinger, 
Germany). Atmospheric and baseline corrections were applied to the data which was presented as 
wavenumber (cm-1) versus normalized absorbance (min = 0.0 and max = 2.0). 
 
3.10. Cystic Fibrosis Ex-Vivo Scnn1b-Tg Mice Pilot Study 
3.10.1 Transgenic Mice Generation and PCR Genotyping 
All animal protocols were approved by the Louisiana State University’s Institutional 
Animal Care and Use Committee. The transgenic mice used for this experiment were Scnn1b-Tg, 
a well-established murine model of CF and COPD [179,250,251]. This C57BL/6N congenic mice 
line over-expresses the β-subunit of the ENaC channel which leads to ASL depletion and CF-like 
mucus obstruction. Moreover, Scnn1b-Tg mice recapitulate many key features of CF including 
high MIP-2, TNF-α, high TGAse activity, and neutrophilia among others [10,164,179,252,253]. 
Genomic DNA extraction from mice tail tissue was performed and transgene-positive animals 






3.10.2 Animal Husbandry 
All the Scnn1b-Tg mice used in this study were maintained in hot-washed, individually 
ventilated cages on a 12-hour dark/light cycle and were fed regular diet and water ad libitum. Mice 
were euthanized after establishment of chronic pulmonary disease, on post-natal day 38.  
 
3.10.3 Trachea Harvesting  
Mice (4 females) were euthanized by avertin injection (300 µl/mice) before being laid 
down (abdomen up) and disinfected (abdomen, thorax and neck) with 70% ethanol. Using clean 
surgical instruments, a horizontal cut from abdomen to neck skin was performed to expose the 
thoracic and neck regions prior to exsanguination via dissection of the abdominal aorta and 
puncturing of the diaphragm. Trachea were exposed by removal of surrounding tissue and were 
removed by dissecting just below the vocal cords and at the carina bifurcation. All trachea were 
placed into a 50 ml conical tube containing 10 ml of cold Ham’s F12 media containing antibiotics. 
In a sterile laminar flow hood, the trachea and Ham’s F12 media containing antibiotics were 
transferred into a 100 mm Petri dish for removal of extraneous tissue (thyroid gland, esophagus, 
etc.). Trachea were transferred to a new Petri dish containing Ham’s F12 with antibiotics (10 ml) 
and cut open lengthwise to expose the lumen. Finally, trachea were placed in a 50 ml conical tube 
containing 10 ml of a solution prepared by mixing 9 ml of cold Ham’s F12 with antibiotics and 1 
ml of a filter-sterilized 1% pronase stock solution. The tube was incubated on a rocker overnight 
at 4°C. Subsequently, MTEC isolation and primary cell cultures were conducted as previously 






3.10.4 MTEC Isolation 
After overnight incubation, 10 ml of Ham’s F12 media containing 20% FBS and antibiotics 
were added to the tube which was then rocked 12 times and let to stand 30 min on ice. Tracheas 
were then transferred to a new conical tube containing 10 ml of Ham’s F12 media with 20% FBS 
and antibiotics using a Pasteur pipette and rocked 12 times. This step was repeated two more times 
and finally the remaining tissue was discarded. The pronase solution along with the three 
supernatants were pooled (50 ml total) and kept on ice at all times prior to centrifugation at 500 x 
g for 5 min at 4°C in a Heraeus Megafuge 16R centrifuge (Thermo Scientific, Kalkberg, Germany). 
The supernatant was discarded and the pellet gently re-suspended and incubated 5 min on ice in 
1 ml of a filter-sterilized DNase solution (0.5 mg/ml) prepared by dissolving 1.0 mg of DNase in 
1.8 ml of Ham’s F12 media containing antibiotics and 200 µl BSA stock solution (10 mg/ml). 
After incubation, the suspension was centrifuged (500 x g for 5 min at 4°C) to discard the 
supernatant and gently re-suspend the pellet in 5 ml of filter-sterilized MTEC basic media 
containing 10% FBS (Table 3.1). For the removal of fibroblasts, the suspension was plated on a 
 
Table 3.1  
MTEC Basic Media (10% FBS) Formulation 
Reagent Final Concentration 
DMEM/Ham's F-12 (HEPES) (1:1) - 
Penicillin-Streptomycin  0.25 µg/ml 
HEPES 15 mM 
Sodium Bicarbonate 3.6 mM 
L-Glutamine 4 mM 





Primaria™ tissue culture dish and incubated at 37°C in an atmosphere of 95% air and 5% CO2 for 
4.5 hours. Following incubation, the cell suspension was collected and the plate was rinsed twice 
with 4 ml MTEC basic media containing 10% FBS. The cell suspension and washes were pooled 
together in a 50 ml conical tube and centrifuged (500 x g for 5 min at 4°C) to discard the 
supernatant and re-suspend the pellet in 4.4 ml of filter-sterilized MTEC media containing Y27632 
ROCK inhibitor (10 µM) (MTEC+Y27632). Cells were counted (10 µl cell suspension + 10 µl 
trypan blue) in a Bio-Rad TC20™ automated cell counter (Bio-Rad Laboratories, Hercules, CA). 
 
3.10.5 MTEC Submerged Culture 
Six Transwell™ polyester membrane inserts were coated with 50 µg type I collagen 
dissolved in 165 µl of a solution prepared by mixing 0.02N sterile acetic acid and collagen stock 
(8.31 µg/µl). The inserts were air-dried in a hood overnight and then exposed to ultraviolet light 
for 30 min before being seeded with 300 µl of the previously prepared cell suspension (9.5 x 104 
cells/insert). MTEC+Y27632 media (1 ml) (Table 3.2) was fed basally and cells were incubated 
overnight at 37°C in an atmosphere of 95% air and 5% CO2. On the first day post-seeding, the 
apical media and non-adherent cells were aspirated. The inserts were then washed twice with 1 ml 
PBS and transferred to a 6-well plate with previously autoclaved teflon rings. The cultures were 
fed every other day with 2.5 ml MTEC+Y27632 media basally and 50 µl apically until confluent 
(7 days). The apical surface was washed gently once a week by adding 0.5 ml of PBS to the insert 
and carefully aspirating with a Pasteur pipette. 
 
3.10.6 MTEC Differentiation in Air-Liquid Interface Culture 
Once confluent, cell cultures were changed to an air-liquid-interface (ALI) in a fresh 6-
well tissue culture plate for differentiation. The cells were fed basally with 2.5 ml of MTEC media 
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Table 3.2  
MTEC+Y27632 Media Formulation  
Reagent Final Concentration 
DMEM/Ham's F-12 (HEPES) (1:1) - 
Penicillin-Streptomycin  100 U/ml: 100 mg/ml 
Insulin 10 µg/ml 
Epidermal Growth Factor 25 ng/ml 
Transferrin 5 µg/ml 
Bovine Pituitary Extract 30 µg/ml 
Retinoic Acid 5x10-8 M 
Fetal Bovine Serum 5% 
Cholera Toxin 0.1 µg/ml 
Y-27632 ROCK inhibitor  10 µM 
 
 
containing Nu-Serum growth medium supplement (MTEC+NuSerum) every other day during 21 
days (Table 3.3). Fresh retinoic acid (5x10-8) was also supplemented to the MTEC+NuSerum 
media every other day during the last 14 days of ALI culture. The apical surface was washed gently 
once a week by adding 0.5 ml of PBS to the insert and carefully aspirating with a Pasteur pipette. 
 
3.10.7 MTEC Treatment with AEB GAGs 
Once cells were differentiated (day 21 of ALI culture) the MTEC cultures were treated 
apically with 350 µl of a solution containing 1.43 mg AEB GAGs/ml in 0.9% saline (0.5 mg AEB 
GAGs/insert). MTEC cultures treated only with the normal saline (350 µl) were used as a control. 
The volume applied apically (350 µl) has been reported in ALI primary tracheal mice [179] and 
the treatment solution was sterilized by autoclaving at 121°C for 5 min as previously reported 
[258,259]. The GAG concentration to be used for this treatment was estimated using as a guideline 
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Table 3.3  
MTEC+NuSerum Media Formulation 
Reagent Final Concentration 
DMEM/Ham's F-12 (HEPES) (1:1) - 
Penicillin-Streptomycin  100 U/ml: 100 mg/ml 




the successful concentrations reported by Gavina and others (100 µg HA/ml for 24 h in-vitro and 
0.5 mg/mice/day for 7 days in-vivo) [10] and Lieb and others (100 µg HA/ml) [224]. Cultures 
were maintained at 37°C in an atmosphere of 95% air and 5% CO2. The treatment was terminated 
by aspiration of the supernatant after 24 h and the supernatants were stored at -80°C for further 
analysis. 
 
3.10.8 Cell Lysis and RNA Purification 
RNA was extracted from MTEC cultures using the RNeasy® Plus Mini Kit (Cat. No. 
14134) from Qiagen (Valencia, CA) following the manufacturer’s instructions in an Air Clean® 
600 PCR Workstation (BioExpress, Kaysville, UT). Appropriate RNA handling techniques were 
applied to avoid contamination. Briefly, cells were disrupted and lysates homogenized using 
QIAshredder spin columns (Qiagen Cat. No. 79654) placed in 2 ml micro-centrifuge tubes which 
were centrifuged for 2 min at maximum speed in a Thermo Scientific Sorvall™ ST 16R Centrifuge 
(Kalkberg, Germany). The homogenized lysates were transferred to gDNA eliminator spin 
columns in 2 ml collection tubes and centrifuged for 30 s at 8,000 x g. The flow-through was saved 
and one volume of 70% ethanol was added and mixed gently by pipetting. The samples were then 
transferred to an RNeasy spin column in a collection tube and centrifuged for 15 s at 8,000 x g to 
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discard the flow-through and elute the RNA from the column by centrifugation with 40 µl of 
RNase-free water. RNA concentration (260 nm) and purity (A260 /A280) in the eluate (1 µl) were 
measured by UV spectrophotometry using the NanoDrop 2000 from Thermo Scientific 
(Wilmington, DE) blanked with RNase-free water. RNA samples (2 ng/µl) were submitted to the 
LSU School of Veterinary Medicine GeneLab for RNA integrity number calculation (RIN) and 
18s and 28s fragment visualization using a Fragment Analyzer™ (Advanced Analytical 
Technologies Inc., Ames, IA). 
 
3.10.9 cDNA Generation and PCR Microarray 
Purified RNA (0.33 µg) was used to generate cDNA using the RT2 First Strad Kit from 
Qiagen which consisted of a genomic DNA elimination step and reverse transcription at 42°C for 
exactly 15 min. SYBR® Green based real-time PCR was performed using a murine CF RT2 
Profiler PCR Array which profiles the expression of 84 key CF genes involved in neutrophil 
chemotaxis, inflammation, immune response and oxidative stress, among others (Table 3.4) in a 
96-well plate format. The arrays included a genomic DNA (GDC), reverse-transcription (RTC) 
and positive PCR controls (PPC). Manufacturer protocols were followed. PCR was conducted in 
a CFX96 Real-Time System equipped with CFX Manager™ Software and automatic threshold 
cycle (CT) calculation from Bio-Rad Laboratories (Hercules, CA). The real-time cycler was first 
programed to cycle for 10 min at 95°C to activate the HotStart DNA Taq Polymerase. This cycle 
was followed by 40 cycles of annealing for 15 s at 95°C and elongation for 1 min at 60°C with 
fluorescence data collection. The temperature ramp rate was adjusted to 1°C/s. Finally, a melting 
curve (65°C to 95°C at 0.5°C /s for 5 s) analysis was conducted to verify PCR specificity, evident 
by a single peak appearing in each reaction at temperatures greater than 80°C. CT values for all 
wells were processed with the SABiosciences PCR Array Data Analysis Web-based software. The 
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software calculated ΔCT (CT Gene of Interest - CT Housekeeping Gene) based on the B2m 
housekeeping gene and then calculated the normalized gene expression values using the formula 
2^-ΔCT. The fold-change values were then converted to fold-regulation. The software also 
performed a hierarchical cluster analysis of the dataset to generate a gene expression heat map 
(fold-regulation >1.5 and p≤0.05) with dendrograms indicating co-regulated genes across arrays. 
A heat map for all the 84 genes analyzed was also generated. 
 
Table 3.4  
Murine CF RT2 Profiler PCR Array Gene List* 
Gene ID Official Name 
CF Modifier Genes 
Adipor2 adiponectin receptor 2 
Gstm2 glutathione S-transferase, mu 2 
Ifrd1 interferon-related developmental regulator 1  
Msra methionine sulfoxide reductase A 
Nos3 (eNOS) nitric oxide synthase 3, endothelial cell  
Tcf7l2 transcription factor 7 like 2, T cell specific 
CFTR Interactors 
Ahsa1 AHA1, activator of heat shock protein ATPase 1 
Canx Calnexin 
Cftr cystic fibrosis transmembrane conductance regulator 
Dnaja1 DnaJ heat shock protein family (Hsp40) member A1 
Dnajc5 DnaJ heat shock protein family (Hsp40) member C5 
Ezr ezrin  
Gopc golgi associated PDZ and coiled-coil motif containing 
Hsp90aa1 (Hspca) heat shock protein 90, alpha (cytosolic), class A member 1  
Hspa4 (Hsp70) heat shock protein 4  
Nme1 (NM23A) NME/NM23 nucleoside diphosphate kinase 1 
Pdzk1 PDZ domain containing 1  
Ppp2r4 protein phosphatase 2 regulatory subunit 4  
Prkaa1 (Ampk) protein kinase, AMP-activated, alpha 1 catalytic subunit 
Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit 
Slc26a3 solute carrier family 26, member 3 
CFTR Interactors 
Slc9a3r1 
solute carrier family 9 (sodium/hydrogen exchanger), member 3 
regulator 1 
Slc9a3r2 
solute carrier family 9 (sodium/hydrogen exchanger), member 3 
regulator 2 
Snap23 synaptosomal-associated protein 23  
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(Table 3.4 continued) 
Gene ID Official Name 
CFTR Interactors 
Stx1a syntaxin 1A 
Stx8 syntaxin 8 
Tjp1 tight junction protein 1 




chemokine (C-C motif) ligand 12  
Cxcr2 (IL-8rβ) chemokine (C-X-C motif) receptor 2  
Edn1 endothelin 1  
Ednra endothelin receptor type A  
IL-1β interleukin 1 beta 
Itgb2 integrin beta 2  
Inflammatory Response 
Ace angiotensin I converting enzyme  
Adrb2 adrenergic receptor, beta 2 
Alox12b arachidonate 12-lipoxygenase, 12R type  
Cxcl1 (Gro1) chemokine (C-X-C motif) ligand 1  
Cxcl3 chemokine (C-X-C motif) ligand 3  
Defb1 defensin beta 1  
IL-10 interleukin 10 
IL-6 interleukin 6 
Mbl2 mannose-binding lectin (protein C) 2  
Pla2g5 phospholipase A2, group V 
Ptgs2 (COX) prostaglandin-endoperoxide synthase 2  
S100a8 S100 calcium binding protein A8  
S100a9 S100 calcium binding protein A9 
Serpina1e serine (or cysteine) peptidase inhibitor 
Tgfb1 transforming growth factor, beta 1  
Tlr2 tool-like receptor 2 
Tlr4 tool-like receptor 4 
Tlr5 tool-like receptor 5 
Tnf tumor necrosis factor 
Tnfrsf11a (Rank) 
tumor necrosis factor receptor superfamily, member 11a, NF-κβ 
activator 
Tnfrsf1a (Tnfr1) tumor necrosis factor receptor superfamily, member 1a 
Immune Response 
Clu clusterin  
Icam1 intercellular adhesion molecule 1 
Lcn2 (NGAL) lipocalin 2 
Mapk1 (Erk2) mitogen-activated protein kinase 1  
NF-Kβ1 





(Table 3.4 continued) 




nuclear factor of kappa light polypeptide gene enhancer in B cells 
inhibitor, alpha 
Prkce protein kinase C, epsilon 
Tnfsf10 (Trail) tumor necrosis factor (ligand) superfamily, member 10  
Fas (Tnfrsf6) Fas (TNF receptor superfamily member 6) 
IL-7r interleukin 7 receptor 
Unfolded Protein Response 
Calr Calreticulin 
Hspa1a (hsp70A1) heat shock protein 1A 
Hspa8 heat shock protein 8 
Hsph1 (hsp105) heat shock 105kDa/110kDa protein 1  
Ion Binding & Transport 
Adk adenosine kinase 
Kcne1 potassium voltage-gated channel, Isk-related subfamily, member 1 
Nr4a2 (Nurr1) nuclear receptor subfamily 4, group A, member 2 
Scnn1b sodium channel, nonvoltage-gated 1 beta  
Scnn1g sodium channel, nonvoltage-gated 1 gamma 
Oxidative Stress 
Dusp1 (Ptpn16) dual specificity phosphatase 1  
Gclc glutamate-cysteine ligase, catalytic subunit 
Sftpb surfactant associated protein B 
Other CF Genes 
Epsti1 epithelial stromal interaction 1 (breast) 
Igfbp5 insulin-like growth factor binding protein 5 
Itga2 integrin alpha 2 
Kit (CD117) kit oncogene  
Met met proto-oncogene 
Prtn3 proteinase 3 
Slpi secretory leukocyte peptidase inhibitor  
*Genes might be relevant in more than one CF pathway. 
 
3.10.10 Transglutaminase Activity Assay 
Extracellular TGAse activity in MTEC was measured spectrophotometrically (450 nm) 
using the TGAse Assay Kit from Sigma-Aldrich (Cat. No. CS1070). Manufacturer’s protocols 
were followed. The assay is based on the TGAse catalysis of a covalent bond formation between 
a free amine group of poly-L-lysine, which is covalently bonded to a 96-well plate surface, and 
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the ƴ-carboxamide group of a biotin substrate buffer. The amount of immobilized biotin was 



























RESULTS AND DISCUSSION 
 
4.1. Yields of Sulfated GAG, HA and Total GAG from Alligator By-products 
Waste by-products of farmed alligators 12 to 18-months old with approximate snout to tail 
length of 4-feet, had mean weights as reported in Table 4.1. These values represent results from 
80 ACS, 400 AFT, 100 ABS and AEB from 200 gator heads. Alligators from different farms and/or 
development stage may or may not conform to this data. 
 
Table 4.1     
Alligator By-product Processing Results        
By-product ACS                     
(n = 80) 
AFT              
(n = 100)* 
ABS              
(n = 100) 
AEB           
(n = 200) 
Weight (g) 942.00 ± 109.12 105.84 ± 6.93 68.44 ± 12.46 2.67 ± 0.19 
Meat Yield (% w/w) 74.34 ± 2.72 - - - 
Bone Yield (% w/w) 22.46 ± 3.88 - - - 
Vitreous Humor Yield 
(% w/w) 
- - - 25.85 ± 2.24 
Means ± SD are shown. ACS = alligator carcasses, AFT = alligator feet, ABS = alligator 
backstraps, AEB = alligator eyeballs. *Average weight of two anterior and two posterior feet is 
reported. 
 
The data presented in Table 4.1 can be used by alligator processors to estimate the value 
of their by-products if used for GAG extraction and estimate the number of alligators needed to 
meet a particular sales need. To the best of our knowledge, this is the first work that reports the 
desinewed meat yield (74.34 ± 2.72%) from ACS. This meat, which contained 17.32 ± 0.02% fat 
(wet basis) as determined by accelerated hexane extraction, might be a business opportunity if 
incorporated into dry protein snacks, sausage, hamburger or pet treat formulations.  
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Purified GAGs from farmed alligator by-products were obtained by a series of optimized 
physical and chemical processes including removal of myofibrillar proteins and fat, enzymatic 
hydrolysis of collagenous protein and purification by dialysis, as well as NaCl-ethanol 
precipitation, heat treatment and lyophilization. The sulfated GAG yields (Table 4.2) as 
determined by the DMB assay were highest (p ≤ 0.05) in ABS (0.22 ± 0.01 mg/g wet ABS), 
followed by AFT, ACS and AEB, in that order. The calibration curve for this assay showed a linear 
relation between the absorption at 525 nm of the chondroitin sulfate-DMB complexes versus 
concentration of CS in the solution, with a correlation coefficient (R2) of 0.975 as shown in 
Figure 4.1.  
Figure 4.1. Standard curve for sulfated GAG assay. 
 
A quantitative analysis of the GAGs extracted from chicken combs demonstrated a sulfated 
GAG concentration (0.2 mg sulfated GAGs/ g wet comb) very similar to our ABS results. The 
content was characterized to be mainly DS and CS [120]. In contrast, a study conducted by Luo 
and others, evaluated the CS yield of chicken keel cartilage and it was shown that every gram of 
wet keel cartilage yielded approximately 24.84 mg of dry CS [125]. Some of the differences that 






















CS Concentration µg/ml 
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might account for the lower sulfated GAG yields obtained in our study compared to keel cartilage 
include: sample type (cartilage only), species, slaughter age, extraction process and purification 
methods. For instance, the chicken keel cartilage study used a 3.5 kDa MWCO membrane which 
might retain more of the typically low molecular weight sulfated GAGs compared to the 14 kDa 
MWCO membrane used in our study. Moreover, hyoid, rib, sternum and trachea cartilages from 
four year-old Thailand crocodiles have also been found to be rich in CS with contents ranging 
from approximately 2.58 to 3.99% on a wet basis [245]. On this research, Garnjanagoochorn and 
others performed an enzymatic cartilage hydrolysis with papain and CS purification using NaCl 
and CPC. Heat treatment (90-95 °C for 10 min) of cartilage samples was conducted beforehand to 
remove meat and connective tissue [245].  
 
Quantitation of HA concentrations by ELISA using a standard curve generated by non-
linear regression analysis (Figure 4.2) revealed yields of 0.60 ± 0.00, 4.62 ± 0.06, 15.31 ± 0.26 and 
0.78 ± 0.01 mg per gram of wet ACS, AFT, ABS and AEB, respectively (Table 4.2). The addition 
of sulfated GAG and HA concentrations is also presented in Table 4.2 as total GAGs (mg/g by-
product). The total concentration of GAGs was calculated to be 0.60 ± 0.00 (0.06% w/w), 4.72 ± 
0.05 (0.47% w/w), 15.53 ± 0.27 (1.55% w/w) and 0.79 ± 0.01 (0.08% w/w) mg/g of wet ACS, 
AFT, ABS and AEB, respectively. Non-sulfated HA accounted for 97.87 – 99.48% of the extracted 
GAGs and the highest yield per gram was obtained from ABS, followed by AFT, AEB and ACS. 
Similar results have been reported for Mediterranean mussels (Mytilus galloprovincialis), in which 
~97% of the extracted GAGs were HA [260]. Based on the average by-product weight data 
reported in Table 4.1 and the average yields reported in Table 4.2 (average by-product weight x 
average total GAG yield), the estimated total GAG yields from one farmed alligator (~4 ft.) are 
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Table 4.2     
Composition of Alligator GAGs       
By-product Sulfated GAGs 
(mg/ g of wet  
by-product) 
HA Content 
(mg/ g of wet 
by-product) 
Total GAGs 
(mg/ g of wet 
by-product) † 
Total GAGs 
(mg/ g of wet 
by-product) †† 
ACS 0.00 ± 0.00c* 0.60 ± 0.00d 0.60 ± 0.00d 0.63 ± 0.03c 
AFT 0.10 ± 0.01b 4.62 ± 0.06b 4.72 ± 0.05b 4.98 ± 0.73b 
ABS 0.22 ± 0.01a 15.31 ± 0.26a 15.53 ± 0.27a 16.66 ± 2.34a 
AEB 0.01 ± 0.01c 0.78 ± 0.01c 0.79 ± 0.01c 0.83 ± 0.04c 
Means ± SD are shown. ACS = alligator carcasses, AFT = alligator feet, ABS = 
alligator backstraps, AEB = alligator eyeballs. 
* Means that do not share a letter within a column are significantly different (p≤0.05). 
† Total GAGs (mg) = Sulfated GAGs (mg) + Hyaluronic Acid (mg)  
†† Total GAGs measured by the 96-well carbazole reaction.  
 
 
Figure 4.2. HA competitive ELISA standard curve 
 
highest in ABS (1.06 g/backstrap), while ACS (0.57 g/carcass) and AFT (0.50 g/4 feet) have 
similar contents, and AEB (0.004 g/2 eyes) have the lowest yield. These results are equivalent to 
approximately 2.13 g GAGs from each alligator. In 2014, a total of 341,887 farmed alligators were 

























slaughtered in Louisiana [39] which means that an estimated 0.73 tons (728.22 Kg) of GAGs could 
have been extracted with over 97% accounting for HA.  
 
The 96-well assay for uronic acid carbazole reaction has been reported to be a sensible and 
reproducible method for the determination of complex uronic acid containing GAGs [248]. In our 
samples, the carbazole assay further confirmed the presence of uronic-acid containing 
polysaccharides (Table 4.2), however there was a slight (4.76 - 6.78%) overestimation of the total 
GAG content compared to the additive procedure (sulfated GAG concentration + HA 
concentration). A study by Frazier and others highlighted the reproducibility of the 96-well 
carbazole assay, however it observed that it may overestimate GAGs in the presence of salts [261]. 
This salt effect might account for the difference in total GAG results due to an increase in 
background absorbance. The calibration curve of the HA standard performed in a 96-well plate is 
shown in Figure 4.3. 
 
Vertebrate tissues and invertebrate species have been largely studied as rich sources of 
sulfated and non-sulfated GAGs [65,120,122–125,245,247,262–264]. For instance, several 
publications have reported yields from chicken combs ranging from 1 to 4 mg hexuronic acid/ g 
wet tissue [120,121,123]. Our higher yields per gram from AFT and ABS indicate that these by-
products are promising when compared to this well-established source of HA. GAGs have also 
been successfully extracted from marine by-products such as shark fin cartilage (~2.45% on a wet 
basis) and ray cartilage (~1.83% on a wet basis). Differences in the yields compared to our research 
are mainly driven by the fact that cartilages were manually separated and cleaned prior to GAG 
extraction which results in higher yields compared to our direct processing of samples as collected 
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Figure 4.3. Calibration curve for HA standard carbazole reaction 
 
from the alligator facilities [245]. Comparison of yields to other marine sources such as salmon 
nasal cartilage (24% w/w on a dry basis) and dogfish cartilage (1.5% w/w on a wet basis) face the 
same constraint [265,266]. Furthermore, in Mediterranean mussels the dry weight yield of GAGs 
was estimated to be 6.1 mg/g (0.6% w/w). These were obtained after defatting with organic 
solvents, extracting by proteolytic treatment and precipitation with NaCl and ethanol [260]. Recent 
work on marine sources of GAGs, reflects that processes for marine GAG extraction are focused 
on obtaining sulfated GAGs [263,264], however lumpsucker fish (Cyclopterus lumpus) dorsal 
humps have a yield of ~40% purified GAGs from wet starting mass and the majority of the extract 
was dominated by non-sulfated high molecular weight HA [247]. Attempts have also been made 
to determine the concentration of GAGs in the body wall of sea cucumbers (Stichopus japonicus). 
Kariya and others reported it to be only 0.03% [267]. In the light of the currently available data for 
animal by-product sources, the process proposed for GAG extraction from ACS, AFT and ABS is 
promising due to the high abundance of these by-products in Louisiana, to the high percentage of 
























non-sulfated HA in the extracts and the high yields per gram obtained particularly in ABS and 
AFT. The main by-product disposed from alligator processing by weight is ACS, therefore its high 
availability in addition to the potential added-value of desinewed meat justify its use for GAG 
extraction despite its lower yield compared to ABS and AFT.  
 
Even with a lower GAG content per alligator, AEB must be considered a viable source of 
HA due to its highly pure abundance in the vitreous humor which facilitates its extraction and 
purification, compared to ACS, AFT and ABS. Moreover, the AEB HA yield obtained in this study 
(0.78 mg/g eyes or ~3.02 mg/g vitreous humor) is much higher than the concentrations reported 
by other studies. This result is at least two times higher than reported contents in bovine vitreous 
humor (0.3 mg/g), swordfish vitreous humor (0.055 mg/g), shark vitreous humor (0.3 mg/g) and 
pig vitreous humor (0.04 mg/g) [124,268]. The differences in GAG contents are thought to be 
mainly due to differences between species and extraction procedures. 
 
4.2. Agarose Gel Electrophoresis of Alligator GAGs 
The molecular weight of GAGs is an important determinant of its biological activity. To 
estimate the molecular weight of ACS, AFT, ABS and AEB GAGs, agarose gel electrophoresis 
was performed following an improved method reported by Cowman and others with slight 
modifications [249]. Figure 4.4 shows the separation of GAG standards and the polydisperse 
molecular weight nature of ACS, AFT, ABS and AEB GAGs on a 0.75% agarose gel stained with 
Stains-All. We observed a primarily blue staining on all samples (lanes 2-5) indicating the presence 
of HA. The polydisperse distribution of molecular weight in HA from animal tissues was evident 
in ACS (~110-1600 kDa), AFT (~70-510 kDa), ABS (~15-1100 kDa) and AEB (~25-1600 kDa) 





Figure 4.4. Electrophoresis of ACS, AFT, ABS and AEB GAGs on 
a 0.75% agarose gel. Lane 1: mixture of Select-HA HiLadder and 
LoLadder (1648, 1138, 940, 667, 509, 310, 213, 111 and 30.2 kDa); 
lane 2: ACS GAGs; lane 3: AFT GAGs; lane 4: ABS GAGs; lane 5: 
AEB GAGs; lane 6: HA salt; lane 7: Chondoitin-4-sulfate salt from 
bovine trachea; lane 8: mixture of Select-HA HiLadder and 
LoLadder. 
 
of sulfated GAGs with Stains-All has been previously reported [269]. The presence of sulfated 
fractions was not observed in AFT, ABS or AEB which might indicate that they migrated faster 
due to their low molecular weight and ran off the gel. Sulfated GAGs from sea cucumbers have a 
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Agarose gel electrophoresis of the GAG samples was also conducted after dialysis in a 
small volume (100 µL) sample chamber with a cellulose membrane against water. Figure 4.5 
indicates that dialysis during 48 hours successfully removed HA below ~28 kDa and LMW 
sulfated GAGs from all samples (see arrow on Figure 4.5). Based on the target market 
requirements, further purification and specific molecular weight separation can be conducted using 
size exclusion chromatography. Our results show that ACS, AFT, ABS and AEB contain HA of 
molecular weights comparable to the HA sizes reported from other animal and microbial sources. 
The molecular weights of HA purified from Mediterranean mussels and eggshells was estimated 
to be about 200 kDa and 50-250 kDa, respectively [246,260,270]. HMW-HA has been reported in 
vitreous humor from fish (1600-2000 kDa) [124]. HA from rooster combs has been reported to 
have a size ranging from 750 to 1200 kDa [123,271]. Microbial fermentation sources report HA 
molecular weights of 538-900 kDa, with wound healing properties proven in the 538 kDa fractions 
[127,246]. Due to their content of beneficially bioactive HMW-HA and MMW-HA, alligator by-
products have a significant commercial potential. 
 
4.3. Enzymatic Assays 
Alligator GAG samples were digested with HAase from bovine testes as negative controls 
to prove that the stainings seen on Figure 4.4 are truly representative of GAGs. Our results (Figure 




Figure 4.5. Electrophoresis of ACS, AFT, ABS and AEB GAGs on 
a 0.75% agarose gel after dialysis (50 kDa MWCO). Lane 1: mixture 
of Select-HA HiLadder and LoLadder (1648, 1138, 940, 667, 509, 
310, 213, 111 and 30.2 kDa); lane 2: ACS GAGs; lane 3: AFT 
GAGs; lane 4: ABS GAGs; lane 5: AEB GAGs; lane 6: HA salt; 
lane 7: Chondoitin-4-sulfate salt from bovine trachea; lane 8: 
mixture of Select-HA HiLadder and LoLadder. 
 
GAG samples which proves the presence of HA and CS in the extracts. HAase randomly 
hydrolyzes 1,4-linkages between GlcNAc and GlcA in HA and 1,4-linkages between GalNAc or 
sulfated GalNAc and GlcA in all types of CS at an optimum pH of 4.5-6.0 [272]. HA degradation 
patterns were similar in all samples with increasing concentrations of HAase resulting in increased 















arrows on Figure 4.6). ABS showed overall HA degradation above 700 kDa and below 33 kDa, 
however some concentration was seen around 300-400 kDa in the 12 and 24 U/µg treatments (ABS 
Figure 4.6. Electrophoresis of ACS, AFT, ABS and AEB GAGs on a 0.75% agarose gel 
after HAase digestion. In all gels lane 1: mixture of Select-HA HiLadder and LoLadder; 
lane 2: 0 U/µg sample; lane 3: 12 U/µg sample; lane 4: 24 U/µg sample; lane 5: 48 U/µg 
sample; lane 6: HA salt; lane 7: Chondoitin-4-sulfate salt from bovine trachea; lane 8: 




lanes 3 and 4). This might be due to accumulation of hydrolyzed HA chains in that particular 
molecular weight or due to transglycosylation. Transglycosylation activity of HAse in the presence 
of 6 to 12 monomer HA units has been previously reported to yield HA oligosaccharides at a pH 
~7 and salt content below 0.5M [273,274].  
 
ChrAse ABC was used to catalyze the degradation of polysaccharides containing 1,4 and 
1,3 linkages. This effect was observed on both non-sulfated and sulfated GAGs in ACS (downward 
arrows on Figure 4.7). The GAGs hydrolyzed by ChrAse ABC include C4S, C6S, DS and HA 
[275,276]. Even though HA is degraded at a lower rate, this effect was clear in our assay (Figure 
4.7). ChrAses A, C, AC and ABC act upon HA, however ChrAse B is specific for cleavage of DS 
[277]. Our results show that the purple stains observed in the agarose gels corresponded to some 
type of CS. Moreover, dialysis or size exclusion chromatography might be better options to 
preserve HMW and MMW HA during the elimination of LMW GAGs.  
 
4.4. Protein and Mineral Contents of Alligator By-product GAGs 
Extracts from ACS, AFT, ABS and AEB were analyzed for presence of residual protein by 
using the BCA assay at 562 nm. Most of these by-products are high in muscle and/or collagenous 
protein content [245]; therefore, a sequential pepsin and papain methodology was conducted to 
yield a clear solution after a total of 16h at 40◦C and 60◦C, respectively. The protein content results 
in the different GAG extracts are shown in Figure 4.8. Previously reported protein content values 
for GAG extracts from animal sources using diverse proteolysis methods are varied. The protein 





Figure 4.7. Electrophoresis of ACS GAGs on a 0.75% agarose gel 
after ChrAse digestion. Lane 1: mixture of Select-HA HiLadder and 
LoLadder (1648, 1138, 940, 667, 509, 310, 213, 111 and 30.2 kDa); 
lane 2: ACS GAGs + 0 U ChrAse; lane 3: ACS GAGs + 0.05 U 
ChrAse; lane 4: ACS GAGs + 0.1 U ChrAse; lane 5: ACS GAGs + 
0.2 U ChrAse; lane 6: HA salt (1500-2200 kDa); lane 7: Chondoitin-
4-sulfate salt from bovine trachea; lane 8: mixture of Select-HA 
HiLadder and LoLadder. 
 
during 6 h at 60◦C, has been estimated to be 1.8 g/100 g dry product (1.8%) [125]. Furthermore, 
GAGs isolated from the body wall of sea cucumbers by proteolytic digestion using actinase at a 
concentration of 50 mg/g of body wall protein, yielded extracts with 3.1% protein content [267]. 
These results are within the range of the ones obtained in our study. Moreover, extraction of low 
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steps including: ultrafiltration-diafiltration, protein electrodeposition, resolubilization in a 
hydroalcoholic medium and precipitation in alkaline hydroalcoholic solution. AEB extracts in our 
 
Figure 4.8. Protein content in alligator by-product GAG extracts 
 
study are similarly of low protein content and high purity (~99%). The AEB protein content is also 
similar to the results of Vijayabaskar and Vaseela which reported the protein content of brown 
marine algae (Sargassum tenerrimum) sulfated GAG extracts to be 0.86 ± 0.42% [278]. Protein 
contents of up to 23.08% have been reported in HA salt from S. zooepidemicus and its wound 
healing properties have been demonstrated [127]. 
 
The main problem in HA purification is the elimination of diverse proteins that may be 
allergenic in some applications [279]. For injection applications (dermal fillers), the ideal final 
protein concentration should be around ~5-10 µg of protein/ mg HA and standards become more 







































European and British Pharmacopoeia require 0.1-0.3% protein in HA [246,280], in the United 
States commercially available HA has been reported to contain up to 4.7% protein [281]. Based 
on this information, AEB may have potential for use in osteoarthritis visco-supplements, 
ophthalmic viscoelastic adjuvants, aesthetic surgery adjuvants, eye drops and topical preparations 
for wound and burn healing, among others. With the current protein contents, ACS (1.8%), AFT 
(2.65%) and ABS (3.68%) GAG extracts could be used for research applications and potentially 
animal nutrition applications. An evaluation of the impurities in HA from different sources was 
conducted by Shieldlin and others. HA powders isolated from rooster comb, bovine vitreous 
humor, and human umbilical cord were purchased from Sigma Chemical Company. All the 
samples contained some amount of protein. The highest levels were detected in HA from human 
umbilical cord (47.7 µg/mg HA) and bovine vitreous humor (36.2 µg/mg HA) [281]. The protein 
content in commercial human umbilical cord HA is ~30% higher than in ABS which has the 
highest protein content among alligator samples. ACS, AFT and AEB also have lower protein 
impurities than the ones reported for commercial HA from human umbilical cord and bovine 
vitreous humor. To the best of our knowledge, there is currently no standard of identity or reference 
standards for HA or sodium hyaluronate in the United States, however protein contents in alligator 
GAGs might need to be further reduced to comply with European medical grade or cosmetic grade 
standards.  
 
The process described in Figure 3.1 includes four unit operations that mainly influence the 
final protein concentration. Namely, removal of muscle proteins with 0.2N NaOH, pepsin and 
papain digestion, dialysis filtration and NaCl-ethanol precipitation of GAGs. This process could 
be further optimized or new processes such as electrodeposition, filtration through activated 
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charcoal or size exclusion chromatography could be incorporated keeping in mind up-scalability 
and economic feasibility. It must be kept in mind that further processing is likely to reduce the 
molecular weight of the extracted materials. For instance, LMW-HA (125 kDa) with no protein 
content has been extracted and purified from commercial eggshells (5.3 mg HA/ g eggshell) using 
acetic acid extraction, isopropanol precipitation and silica gel-activated charcoal purification 
[246].  
 
Mineral contents in alligator by-product GAGs are predominantly sodium as measured by 
ICP-AES (Figure 4.9). The contents were similar in ACS (13.92 ± 0.20 mg/100 mg dry extract), 
AFT (10.64 ± 0.20 mg/100 mg dry extract) and ABS (11.03 ± 0.20 mg/100 mg dry extract) with 
sodium accounting for over 97% in all three extracts. These results were expected in the extracts 
due to the separation of GAGs with NaCl (Figure 3.1). This is in close agreement with what is 
reported in current product specifications from Sigma-Aldrich (St. Louis, MO) for hyaluronic acid 
sodium salt from bovine vitreous humor (3-10% Na). The usage rate of NaCl (2M) in this study 
(Figure 3.1) was determined based on the efficiency of GAG recovery. Addition rates of 1M, 1.5M, 
2M and 4M were evaluated, however no significant increases in GAG yields were observed after 
2M. NaCl (4M) and CPC (10%) were also evaluated in combination and no increase in GAG 
recovery was observed (data not shown). Murado and others reported that NaCl concentrations 
higher than 1.5M should be used for optimal GAG recovery. Lower values of NaCl might lead to 
extracts with higher protein concentrations [124]. AEB GAGs purified without NaCl precipitation, 
as reported in Figure 3.2, had lower total mineral contents (0.27 ± 0.03 mg/100 mg dry extract) 
and cations (Na+ and K+) were the predominant minerals. Physiologically, HA is found in the salt 
form bound to cations [282]. Trace levels of other minerals such as Phosphorus, Sulfur and 
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Calcium were also detected in all samples. The origin of these is thought to be the bones, claws 
and calcified scales in ACS, AFT and ABS, respectively.  
 
Figure 4.9. Mineral content in alligator by-product GAG extracts  
 
4.5. FTIR Spectra of Alligator By-product GAGs 
The FTIR-ATR spectra in the spectral range of 650-4000 cm-1 for GAGs from ACS, AFT, 
ABS and AEB are presented in Figure 4.10. The assignment of FTIR bands for the various samples 
is given in Table 4.3. Commercial Streptococcus sp. HA and bovine trachea CS standards were 
used as references for data analysis and peak identification. All samples and standards displayed a 
strong absorption peak in the range of 3258 cm-1 to 3289 cm-1 suggesting the stretching of -NH or 
-OH in the uronic acid COOH group as expected in GAGs [94]. Lower absorption peaks near 3078 
cm-1 for samples and 3099 cm-1 for standards have been previously identified as the -NH and C=O 
combination in the amino sugar of GAGs while minor stretches at the range of 2890 and 2980 
suggest -CH stretching [127,246,283,284]. The FTIR spectra of alligator samples also revealed the 




















































































































Table 4.3        
Assignment of FTIR Bands for Standards and Alligator GAGs       
FTIR Bands Functional Groups Wavenumber (cm-1) 
HA STD CS STD ACS AFT ABS AEB 
1 O-H or N-H stretching  3271* 3267 3258 3285 3272 3289 
2 N-H with C=O combination 3095 3099 3078 3078 3079 3078 
3 C-H stretching 2890 2891 2935 2959 2937 2980 
4 C=O carboxyl amide I - - 1635 1631 1632 1627 
5 Amide II 1602 1604 1546 1539 1538 1575 
6 N-H deformation 1490 1442 1452 1452 1452 1453 
7 C-O with C=O combination 1407 1409 1399 1399 1393 1404 
8 C-O-H deformation 1375 1375 - - - - 
9 S=O stretching - 1222 1255 1241 1245 1243 
10 C-O-H stretching, C-O and C-O-C 1148 1155 - - 1154 1121 
11  1080 1080 1080 1080 1080 1081 
12  1034 1023 1030 1029 1028 1042 
13 O-H deformation 947 923 922 921 921 925 
14 C-O-C stretching 895 887 882 - - - 
15 C4S Sulfate group - 855 - - - 855 
*Peak absorbance wavenumbers (cm-1) are shown. HA STD = hyaluronic acid standard, CS STD = chondroitin sulfate standard, 
ACS = alligator carcasses, AFT = alligator feet, ABS = alligator backstraps, AEB = alligator eyeballs.  
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1635 cm-1. Although these peaks were not observed in the HA or CS standards, they have been 
reported in haddock (Theragra chalcogramma) and other marine species GAGs as C=O stretching 
in N-acetyl groups of amino sugars or C=O stretching in peptide residues [94,284,285]. The 
secondary amide peaks were centered around 1600 cm-1 for HA and CS standards and were found 
at lower wavenumbers for alligator samples (1538 cm-1 to 1575 cm-1). A peak in the range of 1222 
cm-1 and 1255 cm-1 was observed mainly in the CS standard while alligator samples showed minor 
absorption in this region which is supported by the quantified sulfated GAGs content reported in 
Table 4.1. Accordingly, absorption in the 1200 cm-1 to 1250 cm-1 range was not observed in the 
HA standard [94,284]. Peaks in the range of 1000 cm-1 and 1200 cm-1 (C-OH, C-O and C-O-C) 
have been reported to be fingerprints of pyranose rings which are the building blocks of GAGs 
[286,287]. Below 1000 cm-1, -OH deformations and C-O-C stretches were suggested by Alkrad 
and others [283]. Absorption at 855 cm-1 confirms the presence of chondroitin-4-sulfate [245]. In 
aggregate, the fingerprint functional groups and structures related with GAGs were identified in 
the 650-4000 cm-1 FTIR spectra. Moreover, the FTIR fingerprints of ACS, AFT, ABS and AEB 
reveal broad similarities between them and the findings are comparable with the spectra reported 
in past studies on animal sourced GAGs.  
 
 AFT GAG samples were also submitted to Thermo Fisher Scientific for collection of FTIR 
spectra (Figures 4.11 and 4.12). The FTIR spectra presented a high similarity to the one depicted 
in Figure 4.10, however a sharper definition of the fingerprint region may be due to the use of 
newer and more sensitive equipment. Quenching of some fingerprint signals and the presence of 




Figure 4.11. FTIR spectra of AFT GAGs (top) and streptococcal HA-salt (bottom). 
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4.6. Scnn1b-Tg MTEC Gene Expression Analysis  
To evaluate the potential of AEB GAGs (Figure 4.12) to regulate gene expression in CF-
like MTEC ex-vivo cultures, we took advantage of the well-established Scnn1b-Tg mice line that 
over-expresses the β-subunit of the ENaC channel and presents constitutive airway inflammation. 
The isolation of Scnn1b-Tg MTECs yielded 3.49x105 live cells/trachea which were successfully 
proliferated in a submerged culture and differentiated at ALI into an intact monolayer with a 
cobblestone morphology as previously reported [281]. Murine epithelial primary cultures with 
these characteristics are suitable for the investigation of airway diseases and evaluation of novel 
therapies [257]. The ALI Transwell™ culture system allowed culturing of the MTEC in conditions 
closer to the in-vivo physiological orientation which is an advantage compared to conventional 
media submerged cultures [254].  
 
 
Figure 4.12. Electrophoresis of AEB GAGs used for MTEC 
treatment after dialysis (50 kDa MWCO) and autoclaving 
(121.1°C for 5 min). Lane 1: mixture of Select-HA HiLadder and 
LoLadder (1648, 1138, 940, 667, 509, 310, 213, 111 and 30.2 
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RNA free of any major contaminants was successfully purified from MTEC control and 
treated cultures as indicated by the A260 /A280 of 2.07 ± 0.00 and 2.08 ± 0.01, respectively (Table 
4.4). These RNA quality parameters impact downstream reverse transcription procedures the most 
[289]. High RIN results (Table 4.4) in addition to sharp peaks and bands of rRNA 5S, 18S and 
28S fragments are indicators of RNA with very low degradation (Figure 4.13). RIN values above 
5.5 have been reported to yield high quality outcomes in rt-PCR [290]. Quality control assays of 
the cDNA generation efficiency, genomic DNA contamination, and overall PCR performance 
were passed by all samples. All the arrays presented similar (p≤0.05) reverse-transcription 
efficiencies (average RTC – average PPC ≤ 5) which indicate that the generated data is suitable 
for comparison (Table 4.4). Genomic DNA contamination did not contribute to the fluorescence 
signals captured during real-time PCR (GDC CT ≥ 35) and the overall PCR reproducibility within 
and between arrays passed the manufacturer’s approval parameters (Table 4.4).  
 
Table 4.4.   
RNA Extraction and PCR Control Results   
Reagent Control (saline) AEB GAGs Treated 
RNA A260/A280 Ratio‡ 2.07 ± 0.00*a 2.08 ± 0.01a 
RIN††  9.03 ± 0.06a 8.93 ± 0.15a 
CT GDC§ >35 >35 
Reverse-Transcription Efficiencyφ 3.93 ± 0.06a 4.11 ± 0.26a 
PCR Array ReproducibilityΩ Pass 
* Means that do not share a letter within a row are significantly different. 
‡ A ratio of ~2 is generally accepted as "pure".  
†† Values range from 1 (totally degraded) to 10 (intact). RIN ≥7 is ideal.  
§ GDC CT ≥35 is equal to "Pass".   
φ Average RTC CT - Average PPC CT ≤ 5 is equal to "Pass". 
 
 
Ω If average PPC CT within an array is 20±2 and average PPC CT of any two arrays is not more 
than 2 different from one another, then the sample receives a "Pass". 
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The gene expression analysis of PCR microarray data was conducted by setting a lower 
limit of detection (CT< 35), a ΔRn threshold above the automatically calculated background signal, 
 
 
a fold-regulation threshold (1.5) and normalization to the B2m housekeeping gene which was the 
most stably expressed across the evaluated samples (ΔAverage CT <1). The genes that were not 
detected (9.52%) in at least one of the microarrays were not included in the analysis, namely 
Alox12b, Ccl12, Cxcr2, Il1b, Il10, Il6, S100a8, Serpina1e, Slc26a3. Seventy five (89.29%) of the 
genes analyzed were detected and a heat map depicting their differential expression in MTEC 
cultures is shown in Figure 4.14. After treatment with 0.5 mg AEB GAGs, MTEC gene expression 
was differentially regulated when compared to controls. Without a fold-regulation threshold, 
32.00% (24 genes) of the genes were significantly (p≤0.05) down-regulated and 4.00% (4 genes) 
up-regulated, while the rest of the genes was not significantly (p>0.05) down (42.67%) or up-
regulated (21.33%) (Figure 4.15A). The overall shifts observed in the expression of 75 genes are 
indicative of the multiple signaling properties associated with HA in murine lungs through the  







Figure 4.13. Capillary electrophoresis electropherograms and gels of RNA extracted from 






Figure 4.14. Non-supervised hierarchical clustering heat map of the 
differentially expressed genes in treated and untreated (control) 




Figure 4.15. Distribution of gene regulation due to AEB GAGs treatment of 
Scnn1b-Tg MTEC in ALI culture. A) Plot of significantly (p≤0.05) and not 
significantly regulated genes. B) Plot of significantly (p≤0.05) and not 
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CD44, RHAMM and/or TLR4 [78,79,291,292], however for a more significant view of the 
potential effects of AEB GAGs in gene expression, a volcano plot including a 1.5 fold-regulation 
threshold is shown in Figure 4.15B. Under this criteria, 34.67% of the genes remained unchanged 
after AEB GAG treatment and the percentage of significantly (p≤0.05) regulated genes remained 
unchanged. Evaluation of the gene expression of wild-type MTEC cultures is important for further 
confirmation and understanding of these results. Figure 4.16 presents a non-supervised hierarchical 
clustering heat map with dendrograms which graphically presents differences in the gene 
expression patterns between treated and control cell cultures. Genes are clustered based on 
similarities in their expression patterns and not according to known functional similarities. In order 
of regulation magnitude, the significantly (p≤0.05) up-regulated (>1.5-fold) genes were the Slpi, 
Cxcl1, and Lcn2 (Table 4.5). Following the same criteria, the down-regulated genes were Kit, 
Hsph1, Itga2, Ace, Hsp90aa1, Tgfb1, Slc9a3r2, Ezr, Nfkb1, Slc9a3r1, Igfbp5, Tjp1, Adipor2, 
Prkaa1, Gopc, Prkce, Prkaa2, Ppp2r4, Hspa8, Sftpb, Nr4a2, Tlr4, Calr, and Tcf712. Other genes 
with non-significant (p>0.05) fold-regulation above 2- fold included S100a9 (2.18-fold; p-value= 
0.0778302), Ptgs2 (-3.78-fold; p-value= 0.065190), Edn1 (-2.69-fold; p-value= 0.123140), Dusp1 
(-2.28-fold; p-value= 0.062676), and Dnajc5 (-2.07-fold; p-value= 0.056502). Preliminary 
interpretations of these gene expression regulations suggest potential anti-protease, anti-
inflammatory, and ion-transport homeostatic effects of AEB GAG treatment on Scnn1b-Tg MTEC 
ex-vivo cultures. 
 
The 6.38-fold upregulation of Slpi in AEB GAG treated cells compared to control untreated 
cultures was the highest and most significant (p=0.0019) gene regulation observed in this study 




Figure 4.16. Non-supervised hierarchical clustering heat map with dendrograms indicating co-regulated genes of the significantly 
(p≤0.05) regulated (>1.5 fold) genes in treated and untreated (control) Scnn1b-Tg MTEC in ALI culture. 
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Table 4.5.    
Genes differentially expressed in HA treated vs untreated Scnn1b-Tg MTEC* 




Slpi Protection of epithelial tissues from serine proteases 0.0019 6.38 
Cxcl1 Antimicrobial gene. Neutrophil chemoattractant 0.0349 3.54 
Lcn2 Antibacterial activity & oxidative stress protection  0.0398 2.10 
Down-Regulated 
Kit  MAST cell adhesion to airway epithelia  0.0036 -3.88 
Hsph1  Stress response  0.0110 -3.61 
Itga2 Matrix metalloproteinase-1 positive regulation 0.0066 -3.59 
Ace Vasoconstrictor & pro-inflammatory mediator  0.0011 -3.35 
Hsp90aa1 Endoplasmic reticulum stress response  0.0027 -3.35 
Tgfb1 Fibrosis development & inflammatory response 0.0094 -3.33 
Slc9a3r2 Trans-epithelial sodium/hydrogen absorption  0.0105 -3.25 
Ezr Actin linking to the apical membrane & mucin secretion  0.0305 -3.23 
Nfkb1 Positive regulator of inflammation  0.0471 -2.96 
Slc9a3r1 Trans-epithelial sodium/hydrogen absorption  0.0181 -2.84 
Igfbp5 Fibrosis development & ECM production  0.0030 -2.78 
Tjp1 Regulation of cell polarity & tight junction regulation  0.0148 -2.69 
Adipor2 Regulation of AMPK & PPAR-alpha metabolisms  0.0031 -2.56 
Prkaa1 Metabolic regulation  0.0498 -2.42 
Gopc Ion channel binding  0.0277 -2.41 
Prkce Immune response modulation  0.0023 -2.35 
Prkaa2 Metabolic regulation  0.0188 -2.28 
Ppp2r4 Homeostatic balance of cell metabolism & signaling  0.0359 -2.18 
Hspa8 Protein folding & cellular homeostasis  0.0290 -1.94 
Sftpb Surfactant surface formation  0.0273 -1.94 
Nr4a2 Modulation of inflammation & metabolism 0.0458 -1.92 
Tlr4 Modulation of inflammation & immunity 0.0114 -1.85 
Calr Ca2+ binding & regulation of surface protein expression 0.0333 -1.79 
Tcf7l2 Glucose metabolism & type 2 diabetes susceptibility 0.0193 -1.69 




transcription after LMW-HA (<200 kDa and 0.2% w/v in media) treatment for 18 h [293]. The 
secretory leukocyte protease inhibitor is a serine anti-protease encoded by the Slpi gene and it is 
known to inhibit elastase, cathepsins, trypsin and chymotrypsin [294,295]. Defects in airway 
mucosal defense, including disruption of the homeostatic protease/anti-protease balance, 
contribute to the pathogenesis of obstructive pulmonary disease in CF [296], therefore offsetting 
this imbalance is one of the therapeutic goals in CF management [297,298]. Therapeutic 
approaches have included administration of Slpi and synthetic anti-proteases [295,296]. An in-vivo 
study with sheep exposed to human elastase reported a blockage of elastase-related airway 
responses after treatment with aerosolized HA (150 and 300 kDa) [11]. It has also been reported 
that a single aerosol exposure (20 mg/mice for 50 min) to streptococcal HA (100 kDa) reduced 
elastase-induced airspace enlargement in mice and prevented elastic fiber injury in-vitro [300]. 
Overall, positive results regarding HA protection of airway fibers and regulation of acute lung 
injury have been reported [301], however there are no known reports of HA regulation of the Slpi 
gene in airway epithelial cells as observed in our results. HA has also been reported to immobilize 
and regulate other important components of the airway defense mechanism such as the serine 
protease tissue kallikrein and lactoperoxidase. Regulation of these enzymes is important for 
homeostasis at the apical mucosal surface [79]. The down-regulation of Itga2 (-3.59-fold) further 
supports the potential capacity of AEB GAG treatment to mediate the protease/anti-protease 
imbalance characteristic of CF. Integrin α2β1 is a positive gene expression regulator of the MMP-
1 [302] which is a serine collagenase known to be differentially upregulated during acute and 
chronic lung diseases compared to healthy patients [303,304]. Inhibition of expression or 




Tgfb1 was down-regulated -3.33-fold in AEB GAG treated MTEC (Table 4.5) and it 
encodes the transforming growth factor-β which promotes fibrosis through the deposition of ECM, 
promotes inflammation and modulates immune responses in a cellular and environmental context-
dependent manner [307]. Polymorphisms in the Tgfb1gene have been associated to an accelerated 
decline in lung function of patients with CF [308]. Microarray analyses with cDNA have shown 
that Tgfb1 upregulation alters the expression of multiple genes important for the initiation of acute 
lung injury in nickel exposed mice [309]. A recent (2016) review highlights the fact that fibrosis 
is generally viewed as failed wound healing and that it can eventually lead to loss of lung function 
[310]. This supports the positive implications of Tgfb1 and Igfbp5 (-2.78-fold) downregulation in 
treated cells (Table 4.5). Studies have demonstrated the increased expression of Igfbp5 in mice 
lung tissue after bleomycin-induced fibrosis [311], idiopathic pulmonary fibrosis in human lung 
sections [312], and severe emphysema of smokers in a chromosomal region strongly linked to 
FEV1 [313]. The results discussed so far and the currently available literature point towards an 
important role of AEB GAGs in Snn1b-Tg epithelial tissue protection from excessive degradation 
by proteases and excessive remodeling in airway diseases [314]. The prominent roles of Slpi anti-
protease activity and Tgfb1-related inflammation in wound healing and skin diseases like psoriasis 
suggest that AEB GAGs might also have potential in the treatment of inflammatory skin diseases 
[315–317]. 
 
In addition to protease inhibition, the secretory leukocyte protease inhibitor encoded by 
Slpi, has also been shown to inhibit inflammatory responses via a number of different mechanisms 
including competition with p65 for binding of NF-κβ which in turn prevents its activation and 
inhibition of neutrophil degranulation [296,318]. In our study, anti-inflammatory effects were 
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observed in epithelial cells treated with AEB GAGs which could be dependent or independent of 
Slpi regulation. Down-regulation of Ace (-3.59-fold), Nfkb1 (-2.96-fold), Nr4a2 (-1.92-fold), and 
Tlr4 (-1.85-fold) (Table 4.5) and directionally but not significantly (p>0.05) of Ptgs2 
(Cyclooxygenase-2) (-3.78-fold) support this observation. Angiotensin II is a vasoconstrictor 
related to hypertension, however independently from this role it is also a potent pro-inflammatory 
mediator and inhibition of its converting enzyme encoded by Ace has been beneficial in mice 
pulmonary disease models and for patients with inflammatory diseases [319,320]. Asthmatic 
patients report higher (p≤0.05) serum levels of angiotensin II converting enzyme compared to 
controls and it has been proposed that regulating this imbalance may aid in recovering the system’s 
inflammatory and ROS homeostasis [321]. Interestingly, an association has been reported between 
the severity of CF and the undesirable effects of the Ace gene in Tunisian CF patients [322]. 
Furthermore, angiotensin II is associated with activation of NF-κβ-mediated genes in lung injury 
[323,324]. There is consensus in the fact that NF-κβ-mediated chronic inflammation is a prominent 
feature of CF lung disease and its downstream activation of IL-8 secretion and neutrophil influx 
promote progression of COPD and emphysema [325,326]. Our data further suggests potential anti-
inflammatory properties of AEB GAGs through the modulation of Prkce (-2.35-fold) and Nr4a2 
(-1.92-fold) (Table 4.5). Protein kinase C encoded by Prkce is involved in many signal 
transduction events for several pathways including immune response, bacterial induced 
inflammation, development of COPD and formation of neutrophil extracellular traps (NET) [327–
330]. The protein kinase C dependence for formation of NETs and the pro-inflammatory potential 
of excessive NET formation in CF has been demonstrated [328,331,332]. Therefore the Prkce 
downregulation observed in our study is valuable in supporting the anti-inflammatory effects of 
AEB GAGs. Nr4a2 is a nuclear receptor regulated by Nfkb1, Tgfb1, Ptgs2, and Tlr4 and it 
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modulates inflammation via MMP regulation [333,334]. In a synoviocyte cell line, microarray 
analyses showed that Nr4a2 regulates the transcription of the Il8 gene (+5.04-fold increase vs 
control) [335] and it is also a key regulator of inflammation in rheumatoid arthritis in vitro [336]. 
A highlight of the arthritis study is the remarkable anti-inflammatory effect of streptococcal HA 
(257 kDa) via the attenuation of mRNA expression of Nr4a1, Nr4a1, Nr4a3 and Mmp genes. 
Immune and inflammatory responses can also be mediated by negative regulation of TLRs which 
play a role in lung inflammation and risk of emphysema development [337–339]. In our study, all 
TLRs analyzed (Tlr2, Tlr4, and Tlr5) were downregulated, however only Tlr4 passed the 
thresholds for statistical significance (p≤0.05) and fold-regulation (>1.5-fold). This is of interest 
in our study due to the report that NE can induce Il8 gene expression via Tlr4 in human bronchial 
epithelial cells [340]. It has also been reviewed that in healthy epithelial cells HMW-HA is sensed 
by TLR2 and TLR4 and it protects the integrity of the epithelium by preventing apoptosis. On the 
other hand in injured tissues, HMW-HA is degraded and shorter fragments sensed by TLRs which 
results in inflammatory gene expression [291]. This offers an insight into the potential use of 
continued HMW-HA treatment in diseased airways as a novel therapeutic strategy and area of 
research for the modulation of inflammation. 
 
Kit is a gene that encodes a receptor tyrosine kinase which contributes to mast cell adhesion 
to structural airway epithelial cells [341] and it showed the largest down-regulation (-3.88-fold) of 
all the genes differentially expressed in our study (Table 4.5). Targeting the inhibition of mast cell 
interactions with structural airway cells has been proposed as a novel approach to the treatment of 
asthma [341]. Chronic mast cell activation has undesirable effects on airway function, 
inflammation, and re-modelling in asthma pathophysiology through the production of TNF-α, IL-
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1β, IL-6 and IL-13 mediated by TLR4 activation [342,343]. In CF and idiopathic pulmonary 
fibrosis, the concentration of tryptase and chymase positive mast cells were increased in lung areas 
showing increased inflammation or fibrosis compared to control individuals. These alterations in 
mast cell concentrations correlated positively to lung function parameters [344]. Moreover, mast 
cell serine proteases (tryptase and chymase) have the ability to activate MMP-1 [345]. In our study, 
down-regulation of Ptgs2 (cyclooxygenase-2), which is upregulated in CF, may also reduce the 
release of the inflammatory mediator histamine from mast cells [346,347]. The potential positive 
effects of Kit downregulation after AEB GAG treatment are in agreement with the anti-
inflammatory and protease/anti-protease balance mediation effects previously discussed. 
Altogether, these effects may be contributing to the apparent lower stress response in AEB GAG 
treated MTEC. 
 
 Heat shock proteins (HSP) are mammalian stress proteins produced in response to various 
forms of cellular stress [348]. HSPs also appear to be upregulated with worsening inflammation 
as previously reported in asthma epithelial cells [349,350]. Our results show that Hsph1 (HSP105), 
Hsp90aa1 (HSP90α) and Hspa8 (HSP70) were all significantly (p≤0.05) down-regulated in AEB 
GAG treated cells by -3.61, -3.35 and -1.94-fold, respectively compared to control cultures (Table 
4.5). This a positive outcome given that elevated levels of HSP27. HSP70 and HSP90α in COPD 
are markers for immune activation and tissue destruction [351]. Accordingly, HSP70 and IL-8 
levels in lung epithelial tissues of patients with COPD were significantly increased compared to 
patients without COPD and the results positively correlated with the severity of the disease [352]. 
HSP105 exists as a complex associated with HSP70 [348]. AEB GAG treated MTEC might also 
have been protected against oxidative stress as suggested by Lcn2 upregulation (2.20-fold) (Table 
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4.5). Under conditions of oxidative stress, upregulation of Lcn2 has a protective role against free 
H2O2 radicals and its upregulation can be cancelled by the addition of antioxidants which further 
supports its proposed role [353,354]. In agreement with these findings, Lcn2 has been reported to 
be up to 9.8-fold upregulated in bronchial tissues of individuals exposed to sulfur mustard gas 
compared to controls and an advantageous role in decreasing ROS stress has been proposed [355]. 
Human neutrophil lipocalin-2 is also a key antibacterial component of the innate immune system 
[356] and a biomarker of acute exacerbation in CF [357]. We speculate that in the present study 
the upregulation of Lcn2 may have been protective as a result of nitrosative and oxidative stresses 
which can occur in Scnn1b-Tg mice as mentioned by Livraghi and others [358]. Cxcl1 (3.54-fold) 
was also upregulated in our study (Table 4.5) and its expression is known to be high in non- 
asthmatic airway smooth muscle cells in vivo which limits mast cell chemotaxis [359]. Marcos 
and others recently reported that levels of Cxcl1are high in BAL of Scnn1b-Tg mice compared to 
wild-type littermates, however there was no correlation between its upregulation and free levels of 
DNA or parameters of pulmonary obstruction [360]. Furthermore, this chemokine ligand has been 
reported to contribute to host defense by modulating neutrophil-related bactericidal functions 
[361]. Increased mRNA expression of several genes related to antimicrobial functions has been 
reported after HA treatment of vaginal epithelial cells [293]. To evaluate if the observed 
upregulated antimicrobial gene expressions were not due to contaminants present in the AEB GAG 
preparations (i.e. lipopolysaccharide), the AEB GAG solution used for treatment was analyzed for 
E.coli/coliforms and total aerobic counts (data not shown). Aerobic counts (100-10-3 duplicate 
plates) of the autoclaved treatment solution showed no growth or presence of coliforms, however 
aerobic counts of samples prior to autoclaving showed 68 CFU/ml (100 dilution). It is possible that 
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lipopolysaccharides from dead bacteria in the solution may have contributed to the upregulation 
of Cxcl1 to some extent [362]. 
 
 Slc9a3r2 (-3.25-fold) and Slc9a3r1 (-2.84-fold) were differentially down-regulated by 
AEB GAG treatment in Scnn1b-Tg MTEC (Table 4.5). These genes encode Na+-H+ antiporter 
regulators in the sub-apical membrane of epithelial cells where they play a central role in pH 
regulation and Na+ homeostasis. Moreover, CFTR and Na+-H+ antiporters in renal epithelial cells 
have been shown to interact via a regulatory complex that includes ezrin, encoded by Ezr, and 
protein kinase A, encoded by Prkaa [363,364]. Ezr (-3.23-fold), Prkaa1 (-2.42-fold) and Prkaa2 
(-2.28-fold) were also downregulated by AEB GAG treatment (Table 4.5). These observations 
raise the possibility that AEB GAGs may help modulate the increased Na+ influx in Scnn1b-Tg by 
downregulating Na+-H+ antiporter regulators as well as other components of their regulatory 
complex. In this manner, the airway epithelia could potentially maintain a more optimal ASL 
[365]. A Joint Location-Scale Test very recently highlighted Slc9a3r1, Slc9a3r2, and Ezr for their 
previously unknown role in contributing to CF lung disease [366]. Moreover, Ezr is highly 
expressed in the bronchi of humans with chronic airway diseases and it has been demonstrated that 
it is essential in NE-induced mucin exocytosis which can lead to airway obstruction and bacterial 
colonization [367]. BAL secreted mucin content is increased in Scnn1b-Tg mice [358]. Prkaa1 
and Prkaa2 encode the adenosine mono-phosphate (AMP)-activated kinase (AMPK). AMPK is 
an important regulator of cellular energy homeostasis and [368] and it can be activated by hypoxia, 
oxidative stress , and hyperosmotic stress [369,370]. Altogether, the down regulation of Slc9a3r1, 
Slc9a3r2, Ezr, Prkaa1 and Prkaa2 indicate that AEB GAGs may be mediating Na+ homeostatic 
balance and improvements on the condition of Scnn1b-Tg MTEC ASL ex-vivo [371]. 
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Tight junctions between epithelial cells control paracellular movements of water, ions , and 
solutes, regulate cell polarity and even play a role in airway protection from bacterial infection 
[372–375]. It has been proposed that hypertonic saline solutions increase water transport into the 
ASL which promotes MCC [376]. The suggested mechanism of this action is the opening of the 
tight junctions between epithelial cells which may increase paracellular water transport into the 
airway lumen [377]. In the context of an ex-vivo model using cells over-expressing Na+ channels, 
our observed downregulation of the tight junction protein Tjp1 (-2.69-fold vs control) (Table 4.5), 
along with the Na+ balance regulation previously described, may be another indicator of 
optimization of the ASL conditions through enhanced paracellular permeability. CF airway 
epithelial cells in vitro have tighter tight junctions than healthy cells and [378], however like in 
our study, effects in-vivo in the presence of bacterial insults may cause a different expression of 
Tjp1 and other associated proteins [168,372]. Reports on the effects of HA on tight junctions are 
varied. In human tracheal epithelial cells at ALI, HA (40 KDa) has been reported to enhance Tjp1 
expression and functionality [379], however in human tracheal-bronchial epithelial cells exposed 
to cigarette smoke at ALI, HA (<70 kDa) has been reported to disrupt the tight junctions [380]. 
 
Other genes that were downregulated with AEB GAG treatment were: Adipor2 (-2.56-
fold), Gopc (-2.41-fold), Ppp2r4 (-2.56-fold), Sftpb (-1.94-fold), Calr (-1.79-fold), and Tcf7l2 (-
1.69-fold). Adipor2 (-2.56-fold) (Table 4.5) which encodes for a receptor of adinopectin, has tissue 
and environmental-dependent anti- and pro-inflammatory effects [381]. Adinopectin has been 
proposed as an inflammatory biomarker in COPD due to its rise during exacerbations [382], 
however human and murine studies are still inconclusive regarding its role in inflammation [383]. 
Gopc also known as the Golgi-associated PDZ is a protein involved in vesicle trafficking and is 
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also a negative regulator of CFTR membrane surface levels [384]. Suppression of Gopc has been 
proposed as a pharmacological target as an approach to retaining CFTR at the apical membrane 
[385]. Furthermore, a logistic regression of whole blood gene expression in smoking and non-
smoking individuals identified Gopc as one of the top five genes that predict smoking status [386]. 
Ppp2r4 is a CFTR modifier gene that encodes a regulatory subunit of protein phosphatase 2A and 
it is associated with CFTR deactivation and correlates positively with a worse progression of FEV1, 
lung clearance index and effective specific airway resistance in CF patients [387]. In our study, 
the role of Ppp2r4 downregulation remains unclear given the fact that protein phosphatase 2A 
signaling has shown a critical role in countering inflammatory and proteolytic responses after 
cigarette smoke exposure in mice [388]. The Sftpb gene has shown contradicting results in studies 
in Chinese and German populations. In the Chinese population it protected subjects from COPD 
and increased FEV1 [389], however in Germany a splice variant of Sftpb increased risk of acute 
respiratory failure in COPD [390]. This gene is key to epithelial surfactant homeostasis and is 
known to be overexpressed in CF chronic rhinosinusitis and lipopolysaccharide-induced injury 
[391]. In a 3-year study, surfactant protein B concentrations increased 213% from year 1 to 3 in 
CF patients’ BAL and this correlated positively to decrease in lung function. Interestingly, 
surfactant proteins A, C and D concentrations remained unchanged during the 3-year period but 
there was a progressive loss of their function [392]. In our Scnn1b-Tg ex-vivo study, Sftpb may 
have been downregulated due to a better monolayer hydration which might contribute to make 
surface tension lowering less critical. Calreticulin is a protein encoded by the Calr gene and it is 
involved in Ca2+ binding as well as protein folding, maturation and trafficking [393]. In COPD 
and CF airways, endoplasmic reticulum stress and its Ca2+ stores (calreticulin) promote Ca2+-
dependent hyper-inflammatory responses [394,395]. Some elements of this response are positive 
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such as protective Ca2+ -enhanced MCC, however others such as Ca2+-dependent IL-8 secretion 
are undesirable [396]. Calr downregulation by AEB GAG treatment of MTEC may further 
contribute to ameliorating the inflammatory phenotype of these cultures. 
 
The last downregulation (p≤0.05; >1.5-fold) observed in this study was related to the Tcf7l2 
gene (-1.69-fold) (Table 4.5). This gene confers increased risk of diabetes mellitus on the general 
population and modifies age of onset in CF [15,397]. Tcf7l2 is postulated to play a role in the 
function of the beta cells of pancreatic islets [398] and an in vivo study on mice suggested that 
decreased expression of Tcf7l2 confers reduction of diabetic susceptibility via regulation of the 
metabolism of glucose and lipids [399]. 
 
TGAse activity in the MTEC culture supernatants after AEB GAG treatment was evaluated 
with a method that offers a detection limit of 0.03 mU TGAse/ml. A linear standard curve 
(R2=0.992) with triplicate readings in the 0.03 to 0.35 mU/ml range was developed, however no 
TGAse activity was detected in any of the samples. Further studies are necessary to elucidate the 
role of TGAse in the airways of Scnn1b-Tg mice. 
 
Finally, it is important to mention that the amount of AEB GAGs (0.5 mg/insert of an 
extract containing >98.5% HA (~30-1600 kDa)) used in our experiment is much higher than the 
innate concentrations previously reported in mice BAL (<5 ng/ml in healthy ice and 100-120 ng/ml 
in ozone-exposed mice) [400]. This dose should be enough to compete with any HA present in the 
MTEC ASL and to gain access to cell surface receptors. Furthermore, it has been reported that 
concentrations of CS are low and HS is not detectable in airway secretions, and thus it is unlikely 
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that any innate presence of these GAGs in MTEC ASL contributes or confounds the results 

























CONCLUSIONS AND FUTURE STUDIES 
 
In this research, GAGs were extracted and characterized for the first time from farmed 
Alligator mississippiensis. The extraction and purification methods applied are commonly used to 
purify GAGs and collagen from various animal tissues and sources [260,401–403], however by-
product to solvent ratios, protein removal methods and dialysis times were modified or added for 
GAG extraction from alligator waste carcasses, feet and backstraps. Moreover, a process for GAG 
extraction from alligator eyeball vitreous humor was developed. Of the by-products studied 
carcasses were the bulkiest (942.00 ± 109.12 g/ farmed alligator) and had a total GAG content of 
0.60±0.00 mg/g wet carcass, however backstraps had the highest (p≤0.05) GAG yield (15.53±0.27 
mg/g wet backstrap) and they were easier to extract. This was due to the much less complex nature 
of the backstrap compared to the structure and composition of carcasses, feet and eyeballs. The 
GAGs extracted from all four by-products studied add up to ~2.13 g GAGs per harvest-size (~24 
cm belly-width) farmed alligator or an estimated GAG production of ~0.73 tons/year in Louisiana 
alone based on the 2014 farm-raised harvest data. This indicates that alligators are a potentially 
high yield source of GAGs, which compares favorably to marine sources that have been studied 
and that are generally perceived as “clean” [263]. All extracts contained 0.72-3.68% protein and 
eyeball extracts had the lowest protein content therefore posing the lowest risk of hypersensitivity 
in downstream applications. FTIR revealed spectra showing characteristic animal GAG features 
with which included -OH, -NH and -CH signals, as well as amide signals originated from the 
residual protein content of the samples. The GAGs in all samples were predominantly (>97%) ns-
GAGs or HA with a poly-disperse MW ranging from ~30 to 1600 kDa after a final micro-dialysis 
unit operation. We encountered abundance of HMW and MMW GAGs in Alligator 
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mississippiensis by-products which offers a new potential to improve waste management practices 
and increase revenue in the Louisiana alligator industry through their marketing in the US$1 billion 
global HA market [33] for biomedical, cosmetic, human nutrition and animal nutrition 
applications.  
 
The results of the Scnn1b-Tg MTEC ex-vivo gene expression analysis suggest that alligator 
eyeball GAGs (0.5 mg/ 12 mm insert) may be effective in recovering the protease/anti-protease 
balance through regulation of Slpi (+6.38-fold) and Itga2 (-3.59-fold); reducing inflammation 
through regulation of Kit (-3.88-fold), Ace (-3.35-fold), Nfkb1 (-2.96-fold), Nr4a2 (-1.92-fold), 
and Tlr4 (-1.85-fold); and regulating ASL osmotic homeostasis through regulation of Slc9a3r2  
(-3.25-fold), Slc9a3r1 (-2.84-fold)1, Ezr (-3.23-fold), Prkaa1 (-2.42-fold), and Prkaa2 (-2.28-
fold). The regulation of this triad of key factors in dehydrated airways may have supported an 
apparent lower stress condition as indicated by the downregulation of Hsph1 (-3.61-fold), 
Hsp90aa1 (-3.35-fold) and Hspa8 (-1.94). In conclusion, although the ex-vivo responses to AEB 
GAGs in Scnn1b-Tg MTEC may not be fully predictive of the responses in humans or other 
animal models, our findings indicate the potential importance of AEB GAGs in ameliorating some 
of the negative responses of dehydrated airways in CF. These pilot study results also justify future 
studies to explore other cosmetic or biomedical applications of alligator GAGs which include but 
are not limited to: : wound repair, tumorigenesis, lung injury repair, skin humectation, healing of 
equine joint disease and canine arthritis care. 
 
 It would also be productive to focus future studies deriving from this research on the 
industrial up-scalability to pilot and commercial scale of the processes proposed in Figures 3.1 and 
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3.2, as well as their financial feasibility. It would also be relevant to evaluate the content and 
characteristics of the GAGs contained in the by-products of other Louisiana animals such as 
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